{
    "id": 1216,
    "drugName": "Paclitaxel",
    "terms": [
        "Paclitaxel",
        "Taxol",
        "7-Epipaclitaxel"
    ],
    "synonyms": [
        "7-Epipaclitaxel"
    ],
    "tradeName": "Taxol",
    "drugDescriptions": [
        {
            "description": "Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).",
            "references": [
                {
                    "id": 287,
                    "pubMedId": null,
                    "title": "(NCI Drug Dictionary)",
                    "url": "http://www.cancer.gov/drugdictionary",
                    "authors": null,
                    "journal": null,
                    "volume": null,
                    "issue": null,
                    "date": null,
                    "abstractText": null
                }
            ]
        }
    ],
    "drugClasses": [
        {
            "id": 14,
            "drugClass": "Antimicrotubule Agent"
        },
        {
            "id": 26,
            "drugClass": "BCL2 Family Inhibitor"
        }
    ],
    "createDate": "01/20/2014",
    "clinicalTrials": [
        {
            "nctId": "NCT01946074",
            "title": "A Study of ABT-165 in Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6524,
                    "therapyName": "ABT-165",
                    "synonyms": null
                },
                {
                    "id": 7578,
                    "therapyName": "ABBV-181 + ABT-165 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7577,
                    "therapyName": "ABBV-181 + ABT-165",
                    "synonyms": null
                },
                {
                    "id": 7576,
                    "therapyName": "ABT-165 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6525,
                    "therapyName": "ABT-165 + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "ABT-165 + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02272790",
            "title": "A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1194,
                    "therapyName": "Adavosertib + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1279,
                    "therapyName": "Adavosertib + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1567,
                    "therapyName": "Adavosertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00781612",
            "title": "A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5471,
                    "therapyName": "Ado-trastuzumab emtansine + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 5470,
                    "therapyName": "Ado-trastuzumab emtansine + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 3930,
                    "therapyName": "Ado-trastuzumab emtansine + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1976,
                    "therapyName": "Ado-trastuzumab emtansine + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01732640",
            "title": "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2442,
                    "therapyName": "Afatinib + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02274012",
            "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2441,
                    "therapyName": "Afatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03574649",
            "title": "QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7140,
                    "therapyName": "Carboplatin + Cisplatin + Docetaxel + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7136,
                    "therapyName": "Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel",
                    "synonyms": "NANT non-small cell lung cancer vaccine combination"
                }
            ]
        },
        {
            "nctId": "NCT02187991",
            "title": "Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1679,
                    "therapyName": "Alisertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02051751",
            "title": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1379,
                    "therapyName": "Alpelisib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03725436",
            "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7559,
                    "therapyName": "ALRN-6924 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584478",
            "title": "Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7370,
                    "therapyName": "Anlotinib + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03165994",
            "title": "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5797,
                    "therapyName": "APX005M + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02761694",
            "title": "ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8311,
                    "therapyName": "ARQ 751 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4331,
                    "therapyName": "ARQ 751",
                    "synonyms": null
                },
                {
                    "id": 8310,
                    "therapyName": "ARQ 751 + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04038489",
            "title": "COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8640,
                    "therapyName": "Aspirin + Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02366143",
            "title": "TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2370,
                    "therapyName": "Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1489,
                    "therapyName": "Bevacizumab + Carboplatin + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1203,
                    "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03038100",
            "title": "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2370,
                    "therapyName": "Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03394885",
            "title": "Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1203,
                    "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01633970",
            "title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1203,
                    "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1204,
                    "therapyName": "Atezolizumab + Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1202,
                    "therapyName": "Atezolizumab + Bevacizumab + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02883062",
            "title": "Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1203,
                    "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03498716",
            "title": "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6881,
                    "therapyName": "Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6882,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03800836",
            "title": "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7730,
                    "therapyName": "Atezolizumab + Ipatasertib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7731,
                    "therapyName": "Atezolizumab + Ipatasertib + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03125902",
            "title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5606,
                    "therapyName": "Atezolizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03181100",
            "title": "Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 3049,
                    "therapyName": "Atezolizumab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 5606,
                    "therapyName": "Atezolizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03125928",
            "title": "Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5600,
                    "therapyName": "Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03726879",
            "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 7560,
                    "therapyName": "Atezolizumab + Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 5600,
                    "therapyName": "Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6656,
                    "therapyName": "Atezolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03607955",
            "title": "Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8608,
                    "therapyName": "AVB-S6-500 + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03639246",
            "title": "Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8609,
                    "therapyName": "AVB-S6-500 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8610,
                    "therapyName": "AVB-S6-500 + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1008,
                    "therapyName": "Pegylated liposomal-doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03642132",
            "title": "Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7327,
                    "therapyName": "Carboplatin + Paclitaxel + Talazoparib",
                    "synonyms": null
                },
                {
                    "id": 7326,
                    "therapyName": "Avelumab + Carboplatin + Paclitaxel + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03742102",
            "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer. (BEGONIA)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7545,
                    "therapyName": "Durvalumab + Oleclumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7543,
                    "therapyName": "Durvalumab + Paclitaxel + Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 7544,
                    "therapyName": "AZD9150 + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7541,
                    "therapyName": "Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7542,
                    "therapyName": "Capivasertib + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02138812",
            "title": "Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3448,
                    "therapyName": "BAY1161909 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02366949",
            "title": "Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3447,
                    "therapyName": "BAY1217389 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03737643",
            "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7489,
                    "therapyName": "Bevacizumab + Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704467",
            "title": "Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8253,
                    "therapyName": "Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 7434,
                    "therapyName": "Avelumab + Carboplatin + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01649947",
            "title": "Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1487,
                    "therapyName": "Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1488,
                    "therapyName": "Carboplatin + Hydroxychloroquine + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03740165",
            "title": "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7735,
                    "therapyName": "Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7734,
                    "therapyName": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2104,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01146795",
            "title": "Neoadjuvant Therapy for Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02364999",
            "title": "A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635567",
            "title": "Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2512,
                    "therapyName": "Bevacizumab + Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1812,
                    "therapyName": "Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6522,
                    "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2104,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7515,
                    "therapyName": "Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02810457",
            "title": "Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01239732",
            "title": "A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02039674",
            "title": "A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2104,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 2106,
                    "therapyName": "Ipilimumab + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2107,
                    "therapyName": "Erlotinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2108,
                    "therapyName": "Gefitinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02121990",
            "title": "Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1451,
                    "therapyName": "Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01959490",
            "title": "Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1486,
                    "therapyName": "Bevacizumab + Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1485,
                    "therapyName": "Carboplatin + Docetaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02923739",
            "title": "Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4836,
                    "therapyName": "Bevacizumab + Emactuzumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2123,
                    "therapyName": "Bevacizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01831089",
            "title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1196,
                    "therapyName": "Bevacizumab + Lurbinectedin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1197,
                    "therapyName": "Lurbinectedin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047214",
            "title": "Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2123,
                    "therapyName": "Bevacizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03587311",
            "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7173,
                    "therapyName": "Anetumab ravtansine + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2123,
                    "therapyName": "Bevacizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03745222",
            "title": "A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5871,
                    "therapyName": "BGB-A317",
                    "synonyms": null
                },
                {
                    "id": 7592,
                    "therapyName": "BGB-A317 + Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 7591,
                    "therapyName": "BGB-A317 + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01649336",
            "title": "A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2010,
                    "therapyName": "Binimetinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01297452",
            "title": "BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1183,
                    "therapyName": "Buparlisib + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01572727",
            "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1545,
                    "therapyName": "Buparlisib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01852292",
            "title": "Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1545,
                    "therapyName": "Buparlisib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03997123",
            "title": "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2192,
                    "therapyName": "Capivasertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01625286",
            "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2192,
                    "therapyName": "Capivasertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02383212",
            "title": "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5722,
                    "therapyName": "Carboplatin + Cemiplimab + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 5721,
                    "therapyName": "Carboplatin + Cemiplimab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 5723,
                    "therapyName": "Cemiplimab + Cyclophosphamide + Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 5718,
                    "therapyName": "Cemiplimab + Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 5656,
                    "therapyName": "Cemiplimab",
                    "synonyms": null
                },
                {
                    "id": 5720,
                    "therapyName": "Carboplatin + Cemiplimab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5719,
                    "therapyName": "Cemiplimab + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01316757",
            "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1921,
                    "therapyName": "Carboplatin + Cetuximab + Erlotinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01490749",
            "title": "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1924,
                    "therapyName": "Carboplatin + Cetuximab + Everolimus + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124707",
            "title": "Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1989,
                    "therapyName": "Carboplatin + Cetuximab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03174275",
            "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5873,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03348904",
            "title": "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6740,
                    "therapyName": "Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6738,
                    "therapyName": "Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6736,
                    "therapyName": "Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822496",
            "title": "Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1375,
                    "therapyName": "Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01612351",
            "title": "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2477,
                    "therapyName": "Carboplatin + Cisplatin + Lapatinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2476,
                    "therapyName": "Carboplatin + Lapatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04025879",
            "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8603,
                    "therapyName": "Carboplatin + Cisplatin + Nivolumab + Paclitaxel + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6132,
                    "therapyName": "Carboplatin + Cisplatin + Paclitaxel + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03215706",
            "title": "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6132,
                    "therapyName": "Carboplatin + Cisplatin + Paclitaxel + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02957968",
            "title": "Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5729,
                    "therapyName": "Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01440998",
            "title": "Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1819,
                    "therapyName": "Carboplatin + Dasatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03486314",
            "title": "A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7411,
                    "therapyName": "Carboplatin + Docetaxel + MLN4924 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7410,
                    "therapyName": "MLN4924 + Rifampin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122185",
            "title": "Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                },
                {
                    "id": 1827,
                    "therapyName": "Carboplatin + Docetaxel + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03509012",
            "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5305,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 6905,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6904,
                    "therapyName": "Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 6903,
                    "therapyName": "Cisplatin + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5306,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02726997",
            "title": "Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02962063",
            "title": "Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03872505",
            "title": "Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03800134",
            "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7461,
                    "therapyName": "Cisplatin + Durvalumab + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 7650,
                    "therapyName": "Carboplatin + Durvalumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5630,
                    "therapyName": "Cisplatin + Durvalumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658214",
            "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8330,
                    "therapyName": "Cisplatin + Durvalumab + Fluorouracil + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8329,
                    "therapyName": "Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8328,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8327,
                    "therapyName": "Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8326,
                    "therapyName": "Carboplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8325,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 7524,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02684227",
            "title": "Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3681,
                    "therapyName": "Carboplatin + Enzalutamide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03085914",
            "title": "A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5483,
                    "therapyName": "Epacadostat + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": "Epacadostat  + Nivolumab + FOLFOX"
                },
                {
                    "id": 5484,
                    "therapyName": "Epacadostat + Gemcitabine + Nab-paclitaxel + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5485,
                    "therapyName": "Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5486,
                    "therapyName": "Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 5487,
                    "therapyName": "Cyclophosphamide + Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02044601",
            "title": "Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1370,
                    "therapyName": "Carboplatin + Onartuzumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1371,
                    "therapyName": "Carboplatin + Erlotinib + Onartuzumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01183559",
            "title": "A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2071,
                    "therapyName": "Carboplatin + Fluorouracil + Paclitaxel + Vandetanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03206177",
            "title": "Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6265,
                    "therapyName": "Carboplatin + Galunisertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02920450",
            "title": "Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4785,
                    "therapyName": "Carboplatin + Gedatolisib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446600",
            "title": "Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 8341,
                    "therapyName": "Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920839",
            "title": "INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8194,
                    "therapyName": "Carboplatin + INCMGA00012 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8191,
                    "therapyName": "Cisplatin + Gemcitabine + INCMGA00012",
                    "synonyms": null
                },
                {
                    "id": 8192,
                    "therapyName": "Cisplatin + INCMGA00012 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 8193,
                    "therapyName": "Carboplatin + INCMGA00012 + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03853707",
            "title": "Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7964,
                    "therapyName": "Carboplatin + Ipatasertib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7963,
                    "therapyName": "Carboplatin + Ipatasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03044613",
            "title": "Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5304,
                    "therapyName": "Carboplatin + Ipilimumab + Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03663166",
            "title": "Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7479,
                    "therapyName": "Cisplatin + Ipilimumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7478,
                    "therapyName": "Carboplatin + Ipilimumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7477,
                    "therapyName": "Cisplatin + Etoposide + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03840902",
            "title": "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 7868,
                    "therapyName": "Cisplatin + Etoposide + M7824",
                    "synonyms": null
                },
                {
                    "id": 7869,
                    "therapyName": "Carboplatin + M7824 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7870,
                    "therapyName": "Cisplatin + M7824 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02050009",
            "title": "Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1381,
                    "therapyName": "Carboplatin + Metformin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02065687",
            "title": "Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1381,
                    "therapyName": "Carboplatin + Metformin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03812393",
            "title": "Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7761,
                    "therapyName": "Carboplatin + Neratinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 828,
                    "therapyName": "Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03944915",
            "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8378,
                    "therapyName": "Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03107182",
            "title": "Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5581,
                    "therapyName": "Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03245892",
            "title": "A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03342911",
            "title": "Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03604991",
            "title": "Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829722",
            "title": "Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02944396",
            "title": "Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5054,
                    "therapyName": "Carboplatin + Paclitaxel + Pemetrexed + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 5053,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel + Pemetrexed + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01616303",
            "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1190,
                    "therapyName": "Carboplatin + Oregovomab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694002",
            "title": "Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1726,
                    "therapyName": "Carboplatin + Paclitaxel + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02513563",
            "title": "AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106546",
            "title": "Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530437",
            "title": "A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1587,
                    "therapyName": "Taladegib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01769391",
            "title": "A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 826,
                    "therapyName": "Necitumumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711541",
            "title": "Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1544,
                    "therapyName": "Carboplatin + Etoposide + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1849,
                    "therapyName": "Cisplatin + Fluorouracil + Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01993810",
            "title": "Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02574078",
            "title": "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8314,
                    "therapyName": "Crizotinib + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8313,
                    "therapyName": "Erlotinib + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8312,
                    "therapyName": "Nivolumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 2111,
                    "therapyName": "Bevacizumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1834,
                    "therapyName": "Carboplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 2634,
                    "therapyName": "Carboplatin + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03916419",
            "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01578551",
            "title": "A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01803282",
            "title": "Safety and Tolerability Study in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3320,
                    "therapyName": "GS-5745",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 1779,
                    "therapyName": "Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02998268",
            "title": "Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01196390",
            "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1887,
                    "therapyName": "Carboplatin + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01367002",
            "title": "Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02730546",
            "title": "Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00980954",
            "title": "Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01386385",
            "title": "Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1544,
                    "therapyName": "Carboplatin + Etoposide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02220894",
            "title": "Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02775435",
            "title": "A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2634,
                    "therapyName": "Carboplatin + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966003",
            "title": "Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2141,
                    "therapyName": "Bevacizumab-awwb",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03884101",
            "title": "Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03322566",
            "title": "Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02476955",
            "title": "Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 635,
                    "therapyName": "Miransertib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00979212",
            "title": "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02492867",
            "title": "A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03914612",
            "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00954174",
            "title": "Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",
            "phase": "Phase III",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1125,
                    "therapyName": "Ifosfamide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02713386",
            "title": "Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02718417",
            "title": "Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02051868",
            "title": "International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT)",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1833,
                    "therapyName": "Cisplatin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02453282",
            "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03003962",
            "title": "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02032277",
            "title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02520154",
            "title": "Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02591615",
            "title": "Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02876107",
            "title": "A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 3386,
                    "therapyName": "Carboplatin + Paclitaxel + Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124421",
            "title": "Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1812,
                    "therapyName": "Cisplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01506609",
            "title": "The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1193,
                    "therapyName": "Temozolomide + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1544,
                    "therapyName": "Carboplatin + Etoposide + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02436993",
            "title": "Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02163694",
            "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5274,
                    "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02525757",
            "title": "MPDL3280A With Chemoradiation for Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02272413",
            "title": "Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02542293",
            "title": "Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02186847",
            "title": "Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03036488",
            "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1087,
                    "therapyName": "Cyclophosphamide + Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02412371",
            "title": "A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02429843",
            "title": "A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1242,
                    "therapyName": "Carotuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01868022",
            "title": "Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1857,
                    "therapyName": "Cisplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 2899,
                    "therapyName": "GSK3052230",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02593175",
            "title": "Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3386,
                    "therapyName": "Carboplatin + Paclitaxel + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02630823",
            "title": "MK-3475 Immunotherapy in Endometrial Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03976362",
            "title": "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5591,
                    "therapyName": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5342,
                    "therapyName": "Olaparib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03064490",
            "title": "Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02617849",
            "title": "Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02621398",
            "title": "Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02549209",
            "title": "Pembro/Carbo/Taxol in Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834975",
            "title": "Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02766582",
            "title": "Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631784",
            "title": "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6798,
                    "therapyName": "Cisplatin + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02789657",
            "title": "BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4235,
                    "therapyName": "Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03206645",
            "title": "PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6266,
                    "therapyName": "Carboplatin + Paclitaxel + PTC596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03056833",
            "title": "Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5333,
                    "therapyName": "Carboplatin + Paclitaxel + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430882",
            "title": "TAK228 With Carbo and Taxol in Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6690,
                    "therapyName": "Carboplatin + Paclitaxel + Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02269293",
            "title": "Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2640,
                    "therapyName": "Carboplatin + Paclitaxel + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03064854",
            "title": "PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6027,
                    "therapyName": "Carboplatin + Paclitaxel + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6026,
                    "therapyName": "Cisplatin + Pemetrexed + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6025,
                    "therapyName": "Cisplatin + Gemcitabine + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6024,
                    "therapyName": "Carboplatin + Cisplatin + Pemetrexed + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02317874",
            "title": "Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7327,
                    "therapyName": "Carboplatin + Paclitaxel + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02358200",
            "title": "Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7327,
                    "therapyName": "Carboplatin + Paclitaxel + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01912625",
            "title": "Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2196,
                    "therapyName": "Carboplatin + Paclitaxel + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03307785",
            "title": "Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6322,
                    "therapyName": "Carboplatin + Paclitaxel + TSR-042",
                    "synonyms": null
                },
                {
                    "id": 6321,
                    "therapyName": "Niraparib + TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01636622",
            "title": "Study of Vemurafenib, Carboplatin, and Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1209,
                    "therapyName": "Carboplatin + Paclitaxel + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02071862",
            "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5280,
                    "therapyName": "CB-839 + Everolimus",
                    "synonyms": null
                },
                {
                    "id": 8272,
                    "therapyName": "CB-839 + Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 8273,
                    "therapyName": "CB-839 + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1667,
                    "therapyName": "CB-839",
                    "synonyms": null
                },
                {
                    "id": 8271,
                    "therapyName": "CB-839 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6859,
                    "therapyName": "Cabozantinib + CB-839",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01133678",
            "title": "Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1790,
                    "therapyName": "Cetuximab + Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00660218",
            "title": "A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1988,
                    "therapyName": "Cetuximab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568422",
            "title": "CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7713,
                    "therapyName": "CFI-402257 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02776917",
            "title": "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4313,
                    "therapyName": "Cirmtuzumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03367871",
            "title": "Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6522,
                    "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01194869",
            "title": "Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1534,
                    "therapyName": "Cisplatin + Paclitaxel + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01411410",
            "title": "Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1276,
                    "therapyName": "Copanlisib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03193918",
            "title": "Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5943,
                    "therapyName": "Crenolanib + Paclitaxel + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03285607",
            "title": "MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6236,
                    "therapyName": "Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01008150",
            "title": "Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1504,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1503,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1505,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03101748",
            "title": "3HT With Taxol for Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3187,
                    "therapyName": "Neratinib + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1505,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02379585",
            "title": "Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01275677",
            "title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1503,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1881,
                    "therapyName": "Cyclophosphamide + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1882,
                    "therapyName": "Cyclophosphamide + Docetaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02132949",
            "title": "A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1895,
                    "therapyName": "Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01042379",
            "title": "I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1218,
                    "therapyName": "Trebananib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 746,
                    "therapyName": "Ganitumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1494,
                    "therapyName": "MK2206 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1493,
                    "therapyName": "Trastuzumab + Trebananib",
                    "synonyms": null
                },
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02637375",
            "title": "A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03725059",
            "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7723,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6882,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7722,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03554109",
            "title": "QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7134,
                    "therapyName": "Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel",
                    "synonyms": "NANT triple negative breast cancer vaccine combination"
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329378",
            "title": "Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6435,
                    "therapyName": "Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6434,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03493854",
            "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6434,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02876302",
            "title": "Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4679,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03433313",
            "title": "Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7765,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 7764,
                    "therapyName": "Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01106898",
            "title": "Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1980,
                    "therapyName": "Cyclophosphamide + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01750073",
            "title": "Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1980,
                    "therapyName": "Cyclophosphamide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02654119",
            "title": "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1898,
                    "therapyName": "Cyclophosphamide + Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03395080",
            "title": "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6244,
                    "therapyName": "DKN-01",
                    "synonyms": null
                },
                {
                    "id": 6254,
                    "therapyName": "DKN-01 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013154",
            "title": "A Study of DKN-01 in Combination With Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6254,
                    "therapyName": "DKN-01 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822613",
            "title": "Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2282,
                    "therapyName": "Docetaxel + Irinotecan + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2283,
                    "therapyName": "Alpelisib + LJM716",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564263",
            "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2282,
                    "therapyName": "Docetaxel + Irinotecan + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02569242",
            "title": "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3045,
                    "therapyName": "Docetaxel + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00565851",
            "title": "Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 3045,
                    "therapyName": "Docetaxel + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03474107",
            "title": "A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4125,
                    "therapyName": "Enfortumab vedotin",
                    "synonyms": null
                },
                {
                    "id": 6936,
                    "therapyName": "Docetaxel + Paclitaxel + Vinflunine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03907475",
            "title": "Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3100,
                    "therapyName": "Durvalumab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8594,
                    "therapyName": "Capecitabine + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 8593,
                    "therapyName": "Durvalumab + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 7782,
                    "therapyName": "Durvalumab + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 7541,
                    "therapyName": "Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7781,
                    "therapyName": "Carboplatin + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01494688",
            "title": "A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2843,
                    "therapyName": "Emactuzumab",
                    "synonyms": null
                },
                {
                    "id": 4249,
                    "therapyName": "Emactuzumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02689427",
            "title": "Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3725,
                    "therapyName": "Enzalutamide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02929576",
            "title": "Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 3725,
                    "therapyName": "Enzalutamide + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03246074",
            "title": "Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6670,
                    "therapyName": "Fostamatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02672475",
            "title": "Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3541,
                    "therapyName": "Galunisertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02060253",
            "title": "Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1579,
                    "therapyName": "Ganetespib + Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02562898",
            "title": "Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3259,
                    "therapyName": "Gemcitabine + Ibrutinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02599324",
            "title": "A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7471,
                    "therapyName": "Cetuximab + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 8293,
                    "therapyName": "Ibrutinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8292,
                    "therapyName": "Everolimus + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 8294,
                    "therapyName": "Docetaxel + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03314935",
            "title": "A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6344,
                    "therapyName": "INCB001158 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6343,
                    "therapyName": "Cisplatin + Gemcitabine + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 6342,
                    "therapyName": "Fluorouracil + INCB001158 + Leucovorin + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01593228",
            "title": "Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1173,
                    "therapyName": "Carboplatin + Doxorubicin + Iniparib",
                    "synonyms": null
                },
                {
                    "id": 1172,
                    "therapyName": "Iniparib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1171,
                    "therapyName": "Iniparib + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1170,
                    "therapyName": "Iniparib + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1169,
                    "therapyName": "Carboplatin + Gemcitabine + Iniparib",
                    "synonyms": null
                },
                {
                    "id": 1168,
                    "therapyName": "Iniparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03112590",
            "title": "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5548,
                    "therapyName": "interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02162719",
            "title": "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1588,
                    "therapyName": "Ipatasertib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03337724",
            "title": "A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1588,
                    "therapyName": "Ipatasertib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03573947",
            "title": "Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7605,
                    "therapyName": "Ipilimumab + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894540",
            "title": "A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8120,
                    "therapyName": "IPN60090",
                    "synonyms": null
                },
                {
                    "id": 8121,
                    "therapyName": "IPN60090 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8122,
                    "therapyName": "IPN60090 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00790816",
            "title": "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1410,
                    "therapyName": "Lapatinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1399,
                    "therapyName": "Capecitabine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1497,
                    "therapyName": "Lapatinib + Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1498,
                    "therapyName": "Capecitabine + Lapatinib + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1499,
                    "therapyName": "Gemcitabine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1500,
                    "therapyName": "Docetaxel + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1501,
                    "therapyName": "Fluorouracil + Lapatinib + Leucovorin + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1502,
                    "therapyName": "Fluorouracil + Irinotecan + Lapatinib + Leucovorin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02788708",
            "title": "Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4236,
                    "therapyName": "Lenvatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101788",
            "title": "Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2173,
                    "therapyName": "Letrozole + Paclitaxel + Pegylated liposomal-doxorubicin + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03154294",
            "title": "Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5731,
                    "therapyName": "MLN1117 + Paclitaxel + Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327169",
            "title": "A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2175,
                    "therapyName": "MLN2480 + Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 2176,
                    "therapyName": "Alisertib + MLN2480",
                    "synonyms": null
                },
                {
                    "id": 2177,
                    "therapyName": "MLN2480 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01774851",
            "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1892,
                    "therapyName": "MM-111 + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01325441",
            "title": "A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2586,
                    "therapyName": "Napabucasin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02826161",
            "title": "A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2586,
                    "therapyName": "Napabucasin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02593708",
            "title": "Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3187,
                    "therapyName": "Neratinib + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03742986",
            "title": "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 7433,
                    "therapyName": "Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7547,
                    "therapyName": "Docetaxel + Nivolumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704077",
            "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1721,
                    "therapyName": "Paclitaxel + Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 7433,
                    "therapyName": "Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7431,
                    "therapyName": "Nivolumab + Paclitaxel + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03030287",
            "title": "A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5264,
                    "therapyName": "OMP-305B83 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04055649",
            "title": "ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5978,
                    "therapyName": "ONC201 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03770299",
            "title": "An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02073487",
            "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1583,
                    "therapyName": "Ado-trastuzumab emtansine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01215136",
            "title": "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02470585",
            "title": "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02117024",
            "title": "A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2472,
                    "therapyName": "Cyclophosphamide + HS-110",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02855944",
            "title": "ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 906,
                    "therapyName": "Rucaparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01320592",
            "title": "PD0332991/Paclitaxel in Advanced Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01187199",
            "title": "Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03734029",
            "title": "DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4844,
                    "therapyName": "DS-8201a",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02009449",
            "title": "A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2621,
                    "therapyName": "Pegilodecakin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02419495",
            "title": "Selinexor in Combination With Standard Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01248949",
            "title": "A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1176,
                    "therapyName": "MEDI3617",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02551718",
            "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 690,
                    "therapyName": "Bosutinib",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1740,
                    "therapyName": "Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1746,
                    "therapyName": "Clofarabine",
                    "synonyms": null
                },
                {
                    "id": 1750,
                    "therapyName": "Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 3160,
                    "therapyName": "Nelarabine",
                    "synonyms": null
                },
                {
                    "id": 3159,
                    "therapyName": "Bexarotene",
                    "synonyms": null
                },
                {
                    "id": 3161,
                    "therapyName": "Pentostatin",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 1640,
                    "therapyName": "Mercaptopurine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 1767,
                    "therapyName": "Cladribine",
                    "synonyms": null
                },
                {
                    "id": 1641,
                    "therapyName": "Thioguanine",
                    "synonyms": null
                },
                {
                    "id": 1006,
                    "therapyName": "Daunorubicin",
                    "synonyms": null
                },
                {
                    "id": 877,
                    "therapyName": "Ponatinib",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 751,
                    "therapyName": "Gefitinib",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 640,
                    "therapyName": "Arsenic trioxide",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                },
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1571,
                    "therapyName": "Cabazitaxel",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1327,
                    "therapyName": "Pralatrexate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01641939",
            "title": "A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430843",
            "title": "A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5871,
                    "therapyName": "BGB-A317",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01962948",
            "title": "Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02651610",
            "title": "Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3545,
                    "therapyName": "Bavituximab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01952249",
            "title": "A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2007,
                    "therapyName": "Demcizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02412722",
            "title": "Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01236547",
            "title": "Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03141359",
            "title": "Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038647",
            "title": "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01779050",
            "title": "Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1087,
                    "therapyName": "Cyclophosphamide + Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1982,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1834,
                    "therapyName": "Carboplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1881,
                    "therapyName": "Cyclophosphamide + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01249443",
            "title": "Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02230319",
            "title": "Prevention of Paclitaxel Neuropathy With Cryotherapy",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01493505",
            "title": "TRINOVA-3",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1218,
                    "therapyName": "Trebananib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01653470",
            "title": "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 2545,
                    "therapyName": "BMS-906024",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122770",
            "title": "Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1026,
                    "therapyName": "Itraconazole",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1688,
                    "therapyName": "MLN4924",
                    "synonyms": null
                },
                {
                    "id": 1689,
                    "therapyName": "Fluconazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02514551",
            "title": "A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02341456",
            "title": "Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440425",
            "title": "Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00828009",
            "title": "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2142,
                    "therapyName": "Emepepimut-S",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02322814",
            "title": "A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897441",
            "title": "Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576574",
            "title": "Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178956",
            "title": "A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2057,
                    "therapyName": "Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01357161",
            "title": "A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01454102",
            "title": "Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02788201",
            "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 2563,
                    "therapyName": "Thiotepa",
                    "synonyms": null
                },
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                },
                {
                    "id": 1154,
                    "therapyName": "Dacarbazine",
                    "synonyms": null
                },
                {
                    "id": 640,
                    "therapyName": "Arsenic trioxide",
                    "synonyms": null
                },
                {
                    "id": 1022,
                    "therapyName": "Idarubicin",
                    "synonyms": null
                },
                {
                    "id": 1133,
                    "therapyName": "Mitomycin C",
                    "synonyms": null
                },
                {
                    "id": 1641,
                    "therapyName": "Thioguanine",
                    "synonyms": null
                },
                {
                    "id": 1640,
                    "therapyName": "Mercaptopurine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 1767,
                    "therapyName": "Cladribine",
                    "synonyms": null
                },
                {
                    "id": 1013,
                    "therapyName": "Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1137,
                    "therapyName": "Bleomycin",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 751,
                    "therapyName": "Gefitinib",
                    "synonyms": null
                },
                {
                    "id": 1006,
                    "therapyName": "Daunorubicin",
                    "synonyms": null
                },
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1441,
                    "therapyName": "Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 2206,
                    "therapyName": "Asparaginase",
                    "synonyms": null
                },
                {
                    "id": 781,
                    "therapyName": "Ixabepilone",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                },
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                },
                {
                    "id": 2950,
                    "therapyName": "Estramustine",
                    "synonyms": null
                },
                {
                    "id": 1941,
                    "therapyName": "Floxuridine",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1811,
                    "therapyName": "Carmustine",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 953,
                    "therapyName": "Vandetanib",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 4419,
                    "therapyName": "Toremifene",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 2601,
                    "therapyName": "Dactinomycin",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 3035,
                    "therapyName": "Chlorambucil",
                    "synonyms": null
                },
                {
                    "id": 3161,
                    "therapyName": "Pentostatin",
                    "synonyms": null
                },
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1750,
                    "therapyName": "Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1740,
                    "therapyName": "Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 2635,
                    "therapyName": "Vinblastine",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 1746,
                    "therapyName": "Clofarabine",
                    "synonyms": null
                },
                {
                    "id": 4305,
                    "therapyName": "Teniposide",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1104,
                    "therapyName": "Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 4304,
                    "therapyName": "Streptozocin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                },
                {
                    "id": 4303,
                    "therapyName": "Mechlorethamine",
                    "synonyms": null
                },
                {
                    "id": 4302,
                    "therapyName": "Mitotane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01501487",
            "title": "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I",
            "phase": "FDA approved",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1902,
                    "therapyName": "Cyclophosphamide + Docetaxel + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1982,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 1881,
                    "therapyName": "Cyclophosphamide + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1485,
                    "therapyName": "Carboplatin + Docetaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02312804",
            "title": "Ph Ib/BGJ398/Cervix and Other Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 674,
                    "therapyName": "BGJ398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02389751",
            "title": "A Study of Ganetespib in Combination With Chemoradiation",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631199",
            "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 8068,
                    "therapyName": "Canakinumab + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02134067",
            "title": "Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1400,
                    "therapyName": "TAS-119",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01892046",
            "title": "Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 866,
                    "therapyName": "SNX-5422",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02581943",
            "title": "Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02725268",
            "title": "Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1283,
                    "therapyName": "MLN1117 + Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01281176",
            "title": "High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors",
            "phase": null,
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02301988",
            "title": "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 747,
                    "therapyName": "Ipatasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02502266",
            "title": "Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1001,
                    "therapyName": "Cediranib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02551055",
            "title": "MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                },
                {
                    "id": 3146,
                    "therapyName": "TAK-659",
                    "synonyms": null
                },
                {
                    "id": 1033,
                    "therapyName": "MLN1117",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00989651",
            "title": "Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3047,
                    "therapyName": "Bevacizumab + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02264990",
            "title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00993655",
            "title": "Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01042522",
            "title": "Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1137,
                    "therapyName": "Bleomycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01572038",
            "title": "A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02419417",
            "title": "Study of BMS-986158 in Subjects With Select Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2811,
                    "therapyName": "BMS986158",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01820754",
            "title": "Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02194829",
            "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02229149",
            "title": "Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02620865",
            "title": "Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 1104,
                    "therapyName": "Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2278,
                    "therapyName": "Fluorouracil + Leucovorin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01656538",
            "title": "A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 893,
                    "therapyName": "Reolysin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02625623",
            "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517449",
            "title": "Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01366144",
            "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02483247",
            "title": "A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1945,
                    "therapyName": "BBI503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02819518",
            "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02041533",
            "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02142738",
            "title": "Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01796197",
            "title": "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02581982",
            "title": "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02474173",
            "title": "HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 645,
                    "therapyName": "Onalespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01792050",
            "title": "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 2976,
                    "therapyName": "Indoximod",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01362374",
            "title": "Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 747,
                    "therapyName": "Ipatasertib",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367794",
            "title": "A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01982448",
            "title": "Cisplatin vs Paclitaxel for Triple Neg",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02390427",
            "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02297230",
            "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01407562",
            "title": "Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01015222",
            "title": "Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1032,
                    "therapyName": "Methylnaltrexone",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02302807",
            "title": "A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02437812",
            "title": "Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01281150",
            "title": "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693612",
            "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7628,
                    "therapyName": "GSK3359609 + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02322281",
            "title": "TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 854,
                    "therapyName": "Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1003,
                    "therapyName": "Rociletinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02312245",
            "title": "Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02403895",
            "title": "AZD2014 and Weekly Paclitaxel in Squamous NSCLC",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 991,
                    "therapyName": "Vistusertib",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01107665",
            "title": "Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1143,
                    "therapyName": "Paclitaxel + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01108055",
            "title": "Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1143,
                    "therapyName": "Paclitaxel + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01179269",
            "title": "Stage IIIB/IV Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1143,
                    "therapyName": "Paclitaxel + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631876",
            "title": "PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3574,
                    "therapyName": "Paclitaxel + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 3232,
                    "therapyName": "Mirvetuximab Soravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03136055",
            "title": "Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5643,
                    "therapyName": "Irinotecan + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4021,
                    "therapyName": "Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02734290",
            "title": "Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4022,
                    "therapyName": "Capecitabine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4021,
                    "therapyName": "Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018080",
            "title": "Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4021,
                    "therapyName": "Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03747120",
            "title": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5956,
                    "therapyName": "Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 7583,
                    "therapyName": "Paclitaxel + Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03199885",
            "title": "Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 5956,
                    "therapyName": "Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730833",
            "title": "Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01276041",
            "title": "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01847001",
            "title": "Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1912,
                    "therapyName": "Propranolol",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03716180",
            "title": "DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966471",
            "title": "A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01855828",
            "title": "Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1550,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01525602",
            "title": "Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1395,
                    "therapyName": "Paclitaxel + Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989676",
            "title": "A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin\u00ae [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8261,
                    "therapyName": "Paclitaxel + PF-05280014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03281369",
            "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 6274,
                    "therapyName": "Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Atezolizumab + Cobimetinib + FOLFOX"
                },
                {
                    "id": 6275,
                    "therapyName": "Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Atezolizumab + FOLFOX"
                },
                {
                    "id": 6276,
                    "therapyName": "Atezolizumab + Linagliptin",
                    "synonyms": null
                },
                {
                    "id": 5941,
                    "therapyName": "Atezolizumab + PEGPH20",
                    "synonyms": null
                },
                {
                    "id": 5942,
                    "therapyName": "Atezolizumab + BKT140",
                    "synonyms": null
                },
                {
                    "id": 1721,
                    "therapyName": "Paclitaxel + Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 5850,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03872947",
            "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8046,
                    "therapyName": "Pembrolizumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8078,
                    "therapyName": "Carboplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8047,
                    "therapyName": "Imiquimod + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8079,
                    "therapyName": "Paclitaxel + Ramucirumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8045,
                    "therapyName": "Nivolumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8077,
                    "therapyName": "Cisplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8043,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + TRK-950",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03798626",
            "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8700,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052",
                    "synonyms": null
                },
                {
                    "id": 8702,
                    "therapyName": "Paclitaxel + Ramucirumab + XOMA 052",
                    "synonyms": null
                },
                {
                    "id": 8701,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052",
                    "synonyms": "Bevacizumab + FOLFIRI + XOMA 052"
                },
                {
                    "id": 8703,
                    "therapyName": "Cabozantinib + XOMA 052",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601897",
            "title": "A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4433,
                    "therapyName": "Paclitaxel + Rebastinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02824575",
            "title": "Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4433,
                    "therapyName": "Paclitaxel + Rebastinib",
                    "synonyms": null
                },
                {
                    "id": 4434,
                    "therapyName": "Eribulin + Rebastinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02599363",
            "title": "A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3206,
                    "therapyName": "Paclitaxel + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02661815",
            "title": "A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3469,
                    "therapyName": "Paclitaxel + Ricolinostat",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02041429",
            "title": "Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1369,
                    "therapyName": "Paclitaxel + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02503358",
            "title": "Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4282,
                    "therapyName": "Paclitaxel + Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02195973",
            "title": "Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1620,
                    "therapyName": "Paclitaxel + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03756818",
            "title": "TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7594,
                    "therapyName": "Paclitaxel + TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02779855",
            "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7114,
                    "therapyName": "Paclitaxel + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03554044",
            "title": "Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7119,
                    "therapyName": "Letrozole + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7120,
                    "therapyName": "Talimogene laherparepvec + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 7117,
                    "therapyName": "Exemestane + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7118,
                    "therapyName": "Fulvestrant + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7115,
                    "therapyName": "Anastrozole + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7114,
                    "therapyName": "Paclitaxel + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01862081",
            "title": "A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2321,
                    "therapyName": "Docetaxel + Taselisib",
                    "synonyms": null
                },
                {
                    "id": 2322,
                    "therapyName": "Paclitaxel + Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03085056",
            "title": "Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5493,
                    "therapyName": "Paclitaxel + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01901146",
            "title": "Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1087,
                    "therapyName": "Cyclophosphamide + Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01853748",
            "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03179904",
            "title": "FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5874,
                    "therapyName": "Paclitaxel + Trastuzumab + TVB-2640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01697293",
            "title": "Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3054,
                    "therapyName": "Paclitaxel + Triciribine",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01973309",
            "title": "A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4398,
                    "therapyName": "Paclitaxel + Vantictumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00574587",
            "title": "Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1983,
                    "therapyName": "Paclitaxel + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02892123",
            "title": "Trial of ZW25 in Patients With Advanced HER2-expressing Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8332,
                    "therapyName": "Capecitabine + ZW25",
                    "synonyms": null
                },
                {
                    "id": 6240,
                    "therapyName": "ZW25",
                    "synonyms": null
                },
                {
                    "id": 8333,
                    "therapyName": "Paclitaxel + ZW25",
                    "synonyms": null
                },
                {
                    "id": 8334,
                    "therapyName": "Vinorelbine + ZW25",
                    "synonyms": null
                }
            ]
        }
    ],
    "evidence": [
        {
            "id": 174,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ovarian patients with TP53 deficiency had a 78.6% response rate to Adavosertib (MK-1775) in combination with carboplatin and paclitaxel (J Clin Oncol 31, 2013 (suppl; abstr 5518)).",
            "molecularProfile": {
                "id": 489,
                "profileName": "TP53 inact mut"
            },
            "therapy": {
                "id": 3800,
                "therapyName": "Adavosertib + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4963,
                    "pubMedId": null,
                    "title": "Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).",
                    "url": "http://meetinglibrary.asco.org/content/110824-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinicals study, Adavosertib (MK-1775) in combination with Paclitaxel, demonstrated efficacy in endometrial cancer cells (PMID:24381593).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1567,
                "therapyName": "Adavosertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 504,
                    "pubMedId": 24381593,
                    "title": "Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24381593"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16409,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Afuresertib (GSK2110183) , Paraplatin (carboplatin), and Taxol (paclitaxel) was well-tolerated and demonstrated preliminary efficacy in patients with platinum-resistant epithelial ovarian cancer, resulting in an overall response rate in the dose-expansion part of the trial (Part II) of 32% (9/28) and a median progression-free survival of 7.1 months (PMID: 30563934; NCT01653912).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8020,
                "therapyName": "Afuresertib + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14483,
                    "pubMedId": 30563934,
                    "title": "Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30563934"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6614,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alisertib (MLN8237) and Taxol (paclitaxel) worked synergistically or additively to inhibit tumor growth in cell line and patient-derived xenograft (PDX) models of triple-negative breast cancer (PMID: 24980948).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1679,
                "therapyName": "Alisertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 781,
                    "pubMedId": 24980948,
                    "title": "Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24980948"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1252,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237), alone and in combination with Taxol (paclitaxel), inhibited growth of small cell lung cancer cell (SCLC) lines in culture and inhibited tumor growth in primary human SCLC xenograft models (Mol Cancer Ther 2013;12(11 Suppl):A282).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1679,
                "therapyName": "Alisertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 558,
                    "pubMedId": null,
                    "title": "Antitumor activity of alisertib (MLN8237), an investigational small molecule Aurora A kinase inhibitor, as a single agent and in combination with paclitaxel, in experimental models of small cell lung cancer",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A282"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1755,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Amuvatinib (MP470) in combination with chemotherapeutic agents, demonstrated safety and some efficacy in patients with advanced solid tumors (PMID: 24849582).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2165,
                "therapyName": "Amuvatinib + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2024,
                    "pubMedId": 24849582,
                    "title": "Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24849582"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13038,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6712,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12955,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6706,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10287,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).",
            "molecularProfile": {
                "id": 26179,
                "profileName": "ERBB2 over exp PIK3CA mut"
            },
            "therapy": {
                "id": 5455,
                "therapyName": "ARQ092 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11532,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of ASTX-660 and Taxol (paclitaxel) treatment resulted in tumro regression and achieved partial response in cell line xenograft models of triple-receptor negative breast cancer (Cancer Res 2016;76(14 Suppl):Abstract nr 1287).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6019,
                "therapyName": "ASTX-660 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9603,
                    "pubMedId": null,
                    "title": "The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/1287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15394,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMpower150) that supported FDA approval, Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin resulted in significantly improved median progression-free survival (8.3 vs 6.8 months, HR=0.62, p<0.001) and median overall survival (19.2 vs 14.7 months, HR=0.78, p=0.02) compared to control in patients with metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression and EGFR or ALK mutation status (PMID: 29863955; NCT02366143).",
            "molecularProfile": {
                "id": 30444,
                "profileName": "ALK wild-type EGFR wild-type"
            },
            "therapy": {
                "id": 2370,
                "therapyName": "Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13139,
                    "pubMedId": 29863955,
                    "title": "Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29863955"
                },
                {
                    "id": 15451,
                    "pubMedId": null,
                    "title": "Tecentriq (atezolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1663,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Inlyta (axitinib) in combination with paclitaxel and carboplatin, demonstrated safety and efficacy in patients with advanced solid tumors including ovarian cancers (PMID: 22990652).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1972,
                "therapyName": "Axitinib + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1774,
                    "pubMedId": 22990652,
                    "title": "Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22990652"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10605,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AZD6738 to Taxol (paclitaxel) treatment in a gastric cancer cell line in culture resulted in enhanced chemotherapeutic sensitivity, demonstrating a synergistic effect (PMID: 28138034).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5565,
                "therapyName": "AZD6738 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8664,
                    "pubMedId": 28138034,
                    "title": "AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138034"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4196,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1161909, in combination with Taxol (paclitaxel), had increased efficacy in xenograft models of triple-negative breast cancer compared to Taxol (paclitaxel) alone, resulting in complete tumor regression (PMID: 26832791).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3448,
                "therapyName": "BAY1161909 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5658,
                    "pubMedId": 26832791,
                    "title": "Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832791"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6486,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BAY1161909 and Taxol (paclitaxel) resulted in enhanced growth inhibition compared to Taxol (paclitaxel) alone in non-small cell lung cancer xenograft models (PMID: 26832791).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3448,
                "therapyName": "BAY1161909 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5658,
                    "pubMedId": 26832791,
                    "title": "Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832791"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1217389, in combination with Taxol (paclitaxel), had increased efficacy in inhibiting tumor growth in xenograft models of triple-negative breast cancer, compared to Taxol (paclitaxel) alone (PMID: 26832791).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3447,
                "therapyName": "BAY1217389 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4415,
                    "pubMedId": null,
                    "title": "Novel Mps1 kinase inhibitors with potent anti-tumor activity",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/3090.abstract?cited-by=yes&legid=canres;75/15_Supplement/3090"
                },
                {
                    "id": 5658,
                    "pubMedId": 26832791,
                    "title": "Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832791"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6488,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BAY1217389 and Taxol (paclitaxel) resulted in enhanced growth inhibition compared to Taxol (paclitaxel) alone in non-small cell lung cancer xenograft models (PMID: 26832791).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3447,
                "therapyName": "BAY1217389 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5658,
                    "pubMedId": 26832791,
                    "title": "Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832791"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Bazedoxifene and Taxol (paclitaxel) combination treatment resulted in enhanced inhibition of IL6-induced Gp130/Stat3 signaling and growth of pancreatic cancer cell lines in culture and in cell line xenograft models (PMID: 27535971).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4930,
                "therapyName": "Bazedoxifene + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7003,
                    "pubMedId": 27535971,
                    "title": "Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13982,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of Beleodaq (belinostat), Paraplatin (carboplatin, and Taxol (paclitaxel) in patients with non-small cell lung carcinoma resulted in a 5.7 month median progression-free survival, a partial response in 35% (8/23) patients, and stable disease in 17% (4/23) of patients (Journal of Thoracic Oncology, 2017, vol 12:1S, abstract #P2.03a-003).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6984,
                "therapyName": "Belinostat + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11398,
                    "pubMedId": null,
                    "title": "Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC)",
                    "url": "https://www.jto.org/article/S1556-0864(16)32453-4/pdf?code=jtho-site"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7737,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Avastin (bevacizumab), Xeloda (capecitabine), and Taxol (paclitaxel) resulted in an overall response rate of 77% (44/57), including complete response in 19% (11/57), and a median progression-free survival of 7.6 months and median overall survival of 19.2 months in patients with triple-negative breast cancer (PMID: 27412268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4555,
                "therapyName": "Bevacizumab + Capecitabine + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6463,
                    "pubMedId": 27412268,
                    "title": "Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27412268"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12577,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination therapy of Avastin (bevacizumab), Paraplatin (carboplatin), Taxol (paclitaxel), and Cixutumumab resulted in greater toxicity and did not improve overall survival when compared to Avastin (bevacizumab), Paraplatin (carboplatin), and Taxol (paclitaxel) without Cixutumumab in non-small cell lung carcinoma patients (PMID: 28950351; NCT00955305).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6528,
                "therapyName": "Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10455,
                    "pubMedId": 28950351,
                    "title": "Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950351"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14115,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOG-0218) that supported FDA approval, addition of Avastin (bevacizumab) during and after Paraplatin (carboplatin) plus Taxol (paclitaxel) treatment prolonged progression-free survival (14.1 vs 10.3 months) compared to placebo in patients with previously untreated, stage III/IV epithelial ovarian, primary peritoneal, or fallopian tube cancer (PMID: 22204724; NCT00262847).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1964,
                "name": "fallopian tube cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11465,
                    "pubMedId": 22204724,
                    "title": "Incorporation of bevacizumab in the primary treatment of ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22204724"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14114,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOG-0218) that supported FDA approval, addition of Avastin (bevacizumab) during and after Paraplatin (carboplatin) plus Taxol (paclitaxel) treatment prolonged progression-free survival (14.1 vs 10.3 months) compared to placebo in patients with previously untreated, stage III/IV epithelial ovarian, primary peritoneal, or fallopian tube cancer (PMID: 22204724; NCT00262847).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11465,
                    "pubMedId": 22204724,
                    "title": "Incorporation of bevacizumab in the primary treatment of ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22204724"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11127,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Avastin (bevacizumab) to neoadjuvant chemotherapy (Paraplatin (carboplatin) plus Taxol (paclitaxel)) did not improve complete macroscopic response rate (2/35 vs 2/33), or median progression free survival (20.4 vs 20.1 months) compared to control in patients with advanced epithelial ovarian cancer, but resulted in favorable rate of surgical feasibility (66.7 vs 88.6%) (J Clin Oncol 35, 2017 (suppl; abstr 5508)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9098,
                    "pubMedId": null,
                    "title": "Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)? (GEICO 1205/NOVA TRIAL).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186640.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14034,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase III trial, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11433,
                    "pubMedId": 29191972,
                    "title": "Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29191972"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1975,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In an open-label trial that supported FDA approval, treatment with the combination of Avastin (bevacizumab) with Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved overall survival compared to Paraplatin (carboplatin) and Taxol (paclitaxel) alone in patients with advanced non-small cell lung cancer (PMID: 17602060).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2420,
                    "pubMedId": 17602060,
                    "title": "FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17602060"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14116,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOG-0218) that supported FDA approval, addition of Avastin (bevacizumab) during and after Paraplatin (carboplatin) plus Taxol (paclitaxel) treatment prolonged progression-free survival (14.1 vs 10.3 months) compared to placebo in patients with previously untreated, stage III/IV epithelial ovarian, primary peritoneal, or fallopian-tube cancer (PMID: 22204724; NCT00262847).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1725,
                "name": "peritoneum cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11465,
                    "pubMedId": 22204724,
                    "title": "Incorporation of bevacizumab in the primary treatment of ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22204724"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14033,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase III trial, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11433,
                    "pubMedId": 29191972,
                    "title": "Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29191972"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1984,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, the addition of Avastin (bevacizumab) to Platinol (cisplatin) and Taxol (paclitaxel) chemotherapy resulted in improved overall survival and progression-free survival compared to chemotherapy alone in patients with cervical cancer (PMID: 25281440, PMID: 24552320).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2512,
                "therapyName": "Bevacizumab + Cisplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2893,
                "name": "cervix carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2422,
                    "pubMedId": 25281440,
                    "title": "Bevacizumab and treatment of cervical cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25281440"
                },
                {
                    "id": 2423,
                    "pubMedId": 24552320,
                    "title": "Improved survival with bevacizumab in advanced cervical cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24552320"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3295,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, angiosarcoma patients treated with Avastin (bevacizumab), in combination with Taxol (paclitaxel), showed no improvement in PFS and OS compared to Taxol (paclitaxel) alone and resulted in higher toxicity (PMID: 26215950).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2123,
                "therapyName": "Bevacizumab + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3717,
                    "pubMedId": 26215950,
                    "title": "Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26215950"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1982,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, the addition of Avastin (bevacizumab) to Hycamtin (topotecan) and Taxol (paclitaxel) chemotherapy resulted in improved overall survival and progression-free survival compared to chemotherapy alone in patients with cervical cancer (PMID: 25281440, PMID: 24552320).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2513,
                "therapyName": "Bevacizumab + Paclitaxel + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 2893,
                "name": "cervix carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2422,
                    "pubMedId": 25281440,
                    "title": "Bevacizumab and treatment of cervical cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25281440"
                },
                {
                    "id": 2423,
                    "pubMedId": 24552320,
                    "title": "Improved survival with bevacizumab in advanced cervical cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24552320"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12077,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Mvasi (bevacizumab-awwb) treatment resulted in an objective response rate (ORR) of 39% (128/328) similar to the ORR of Avastin (bevacizumab), 41.7% (131/314), in non-squamous NSCLC patients receiving Carboplatin and Paclitaxel as first line therapy, and was pharmacokinetically similar to Avastin (bevacizumab) further supporting extrapolation to other indications (J Clin Oncol 34, 15_sup (2016) 9095, J Clin Oncol 35, 15_sup (2017) 9050, FDA.gov; NCT01966003).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6255,
                "therapyName": "Bevacizumab-awwb + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10011,
                    "pubMedId": null,
                    "title": "Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9095"
                },
                {
                    "id": 10017,
                    "pubMedId": null,
                    "title": "Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: Pharmacokinetic results and justification for extrapolation across bevacizumab indications.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9050"
                },
                {
                    "id": 15586,
                    "pubMedId": null,
                    "title": "Mvasi (bevacizumab-awwb) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761028"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16186,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, combination therapy with Taxol (paclitaxel) and Mektovi (binimetinib) was tolerable and resulted in an objective response rate of 18% (5/28, 1 complete response, 4 partial responses) and a clinical benefit rate of 57% (16/28, best overall response of stable disease or better) in patients with platinum resistant/refractory epithelial ovarian cancer, and clinical benefit was observed in all patients with MAPK pathway alterations (n=4) (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16187,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Taxol (paclitaxel) and Mektovi (binimetinib) combination therapy demonstrated clinical benefit in three patients with platinum resistant/refractory epithelial ovarian cancer harboring activating mutations in KRAS, with one partial response and one stable disease in patients with KRAS G12D and stable disease in a patient with KRAS G12V (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16188,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Taxol (paclitaxel) and Mektovi (binimetinib) combination therapy demonstrated clinical benefit in three patients with platinum resistant/refractory epithelial ovarian cancer harboring activating mutations in KRAS, with one partial response and one stable disease in patients with KRAS G12D and stable disease in a patient with KRAS G12V (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16190,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent high-grade serous ovarian cancer harboring a TP53 I195T mutation and amplifications of ERBB2, CCNE1, PIK3CA, and SMARCA4 was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for approximately seven months, followed by Mektovi (binimetinib) alone for two months, and was progression-free at four years post-therapy (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 31513,
                "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16189,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent serous ovarian cancer harboring a BRAF-CUL1 fusion was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for 7 months, and achieved a complete response that lasted an additional 25 months followed by disease progression (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 23814,
                "profileName": "CUL1-BRAF"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16424,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BMS-906024 and Taxol (paclitaxel) resulted in synergy in BRAF and KRAS wild-type non-small cell lung cancer (NSCLC) cell lines in culture, but not in cell lines harboring KRAS or BRAF activating mutations, and demonstrated enhanced tumor growth inhibition in cell line and patient-derived xenograft (PDX) models of BRAF, KRAS wild-type NSCLC (PMID: 28978720).",
            "molecularProfile": {
                "id": 28546,
                "profileName": "BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 8027,
                "therapyName": "BMS-906024 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14491,
                    "pubMedId": 28978720,
                    "title": "Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978720"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15872,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Buparlisib (BKM120) in combination with Taxol (paclitaxel) resulted in a durable partial response in a patient with breast metaplastic carcinoma harboring PIK3CA H1047R, with a total response period of 70 weeks and an overall survival of 42 months (PMID: 30577988).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4680,
                "name": "breast metaplastic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13879,
                    "pubMedId": 30577988,
                    "title": "PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30577988"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14021,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival in head and neck squamous cell carcinoma patients with low tumor mutational burden (HR=0.57) (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 29717,
                "profileName": "TMB low"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14020,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival (HR=0.52)  and prolonged progression-free survival (HR=0.45) in head and neck squamous cell carcinoma patients harboring TP53 mutations compared to TP53 wild-type patients (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16716,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12063,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of AZD5363 to Taxol (paclitaxel) did not improve progression free survival compared to placebo (10.9 vs 8.4 months) in patients with Esr1-positive, Erbb2 (Her2)-negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 241PD; NCT01625286).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9995,
                    "pubMedId": null,
                    "title": "BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16718,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 31771,
                "profileName": "AKT1 wild-type PIK3CA wild-type PTEN wild-type"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12064,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30860570; NCT01625286).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14619,
                    "pubMedId": 30860570,
                    "title": "BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30860570"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16715,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (5.9 vs 4.2 months, HR=0.75, p=0.06) and median overall survival (19.1 vs 12.6 months, HR=0.64, p=0.02) compared to placebo in patients with metastatic triple-negative breast cancer (J Clin Oncol 36, no. 15_suppl (May 20 2018) 1007-1007; NCT02423603).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14750,
                    "pubMedId": null,
                    "title": "AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.1007"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 305,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial of patients with advanced NSCLC, the combination of Cediranib (AZD-2171) and carboplatin/paclitaxel (CP) chemotherapy resulted in improved response rate over placebo plus CP, but did not improve progression-free survival, and the study did not proceed to Phase III due to toxicity (PMID: 24360368).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1664,
                "therapyName": "Carboplatin + Cediranib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 95,
                    "pubMedId": 24360368,
                    "title": "Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24360368"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7857,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4581,
                "therapyName": "Carboplatin + Erlotinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6514,
                    "pubMedId": 16043828,
                    "title": "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16043828"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9604,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib had a variable impact on chemoradiation therapy (consisting of Paraplatin (carboplatin), Taxol (paclitaxel), and radiation) in non-small cell lung cancer cell lines in culture and in xenograft models, resulting in increased sensitivity in some cell lines, and decreased sensitivity in others (PMID: 27354472).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5103,
                "therapyName": "Carboplatin + Ganetespib + Paclitaxel + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7285,
                    "pubMedId": 27354472,
                    "title": "Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27354472"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11053,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27904,
                "profileName": "CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H"
            },
            "therapy": {
                "id": 5833,
                "therapyName": "Carboplatin + Imatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7169,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, the combination of Ipafricept (OMP-54F28) with Paraplatin (carboplatin) and Taxol (paclitaxel) was well-tolerated and resulted in complete response in 35% (6/17), partial response in 47% (8/17) and stable disease in 18% (3/17) evaluable patients with recurrent platinum-sensitive ovarian cancer (J Clin Oncol 34, 2016 (suppl; abstr 2515)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4400,
                "therapyName": "Carboplatin + Ipafricept + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6131,
                    "pubMedId": null,
                    "title": "Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).",
                    "url": "http://meetinglibrary.asco.org/content/165914-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1574,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial of patients with advanced or metastatic NSCLC, treatment with Lenvima (lenvatinib) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) was tolerated and demonstrated anti-tumor activity (PMID: 23860537).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1885,
                "therapyName": "Carboplatin + Lenvatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1548,
                    "pubMedId": 23860537,
                    "title": "Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23860537"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1800,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical, Linifanib (ABT-869), in combination with Taxol (paclitaxel) and Paraplatin (carboplatin), increased progression free survival in patients with nonsquamous non-small cell lung cancer (PMID: 25559798).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2310,
                "therapyName": "Carboplatin + Linifanib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2111,
                    "pubMedId": 25559798,
                    "title": "Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25559798"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14487,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEDI3617 in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in no objective response (0/7) and stable disease in 43% (3/7) of patients with advanced solid tumors (PMID: 29559563; NCT01248949).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7098,
                "therapyName": "Carboplatin + MEDI3617 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11647,
                    "pubMedId": 29559563,
                    "title": "Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559563"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12315,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Motesanib (AMG 706) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) did not improve progression-free survival significantly compared to placebo (6.1 vs 5.6 months) in patient with non-squamous non-small cell lung cancer (PMID: 28902534).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6453,
                "therapyName": "Carboplatin + Motesanib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10304,
                    "pubMedId": 28902534,
                    "title": "Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28902534"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3702,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, patients with advanced ovarian cancer treated with Ofev (nintedanib), in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), experienced a progression free survival of 17.2 months versus 16.6 months in patients treated with a combination of placebo, carboplatin, and paclitaxel in first-line treatment (PMID: 26590673).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3234,
                "therapyName": "Carboplatin + Nintedanib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4012,
                    "pubMedId": 26590673,
                    "title": "Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26590673"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3625,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 52% (11/21) of patients with advanced solid tumors demonstrated stable disease when treated with Farydak (panobinostat), in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) (PMID: 22851205).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3202,
                "therapyName": "Carboplatin + Paclitaxel + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3917,
                    "pubMedId": 22851205,
                    "title": "A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22851205"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 436,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Votrient (pazopanib) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) demonstrated efficacy in solid tumors (PMID: 22679111).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1714,
                "therapyName": "Carboplatin + Paclitaxel + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 177,
                    "pubMedId": 22679111,
                    "title": "Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22679111"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15147,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-407) that supported FDA approval, Keytruda (pembrolizumab) in combination with chemotherapy consisted of carboplatin and paclitaxel or nab-paclitaxel significantly improved overall survival (15.9 vs 11.3 months), progression-free survival (6.4 vs 4.8 months), and overall response rate (58% vs 35%) compared to placebo plus chemotherapy in patients with untreated metastatic squamous non-small cell lung cancer (J Clin Oncol 36, no. 15_suppl, 105-105; NCT02775435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2103,
                "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12696,
                    "pubMedId": null,
                    "title": "Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.105"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17053,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Keytruda (pembrolizumab) is in guidelines as first-line therapy for patients with lung squamous cell carcinoma with CD274 (PD-L1) expression of greater than or equal to 1% (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 2103,
                "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 646,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, preliminary results reported a 67% response rate in NSCLC patients treated with Cyramza (ramucirumab) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) (PMID: 22481432).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1726,
                "therapyName": "Carboplatin + Paclitaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 369,
                    "pubMedId": 22481432,
                    "title": "Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22481432"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4087,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring RAF1 amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater progression free survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 17293,
                "profileName": "RAF1 amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4086,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 1413,
                "profileName": "KRAS amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4088,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring CCND1 amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater progression free survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 1420,
                "profileName": "CCND1 amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12184,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring AKT3 W330C demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 28513,
                "profileName": "AKT3 W330C"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12182,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12185,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 4174,
                "profileName": "PTEN R130Q"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12181,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in an objective response rate of 41.7% (15/36), which included all partial responses, and 52.3% (19/36) had stable disease (PMID: 28961834).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12183,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9866,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 5274,
                "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7723,
                    "pubMedId": null,
                    "title": "Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10584,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Veliparib (ABT-888) with Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in both an improved median PFS (5.8 mo vs 4.2 mo) and median OS (11.7 mo vs 9.1 mo) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in patients with non-small cell lung carcinoma (PMID: 27803064).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5274,
                "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8661,
                    "pubMedId": 27803064,
                    "title": "Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27803064"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9867,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 5274,
                "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7723,
                    "pubMedId": null,
                    "title": "Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13980,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) plus Zolinza (vorinostat) compared to the addition of placebo resulted in a greater median progression-free survival (6.0mo vs 4.1mo) and overall survival (13.0 mo vs 9.7 mo) in patients with non-small cell lung carcinoma (PMID: 19933908).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6983,
                "therapyName": "Carboplatin + Paclitaxel + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11397,
                    "pubMedId": 19933908,
                    "title": "Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19933908"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3385,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Pilaralisib (XL147) plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929).",
            "molecularProfile": {
                "id": 13308,
                "profileName": "PIK3CA H1047X KRAS G12X"
            },
            "therapy": {
                "id": 3135,
                "therapyName": "Carboplatin + Paclitaxel + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 300,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I trial, carboxyamidotriazole in combination with Taxol (paclitaxel) displayed safety and efficacy in patients with solid tumors (PMID: 19738417).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1663,
                "therapyName": "Carboxyamidotriazole Orotate  + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 164,
                    "pubMedId": 19738417,
                    "title": "A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19738417"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5274,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT007093 and Taxol (paclitaxel) worked synergistically to inhibit growth of triple-receptor negative breast cancer cell lines in culture (PMID: 20576088).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3807,
                "therapyName": "CCT007093 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4977,
                    "pubMedId": 20576088,
                    "title": "RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576088"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5273,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT007093 and Taxol (paclitaxel) worked synergistically to inhibit growth of breast cancer cell lines over expressing Ppm1d in culture (PMID: 20576088).",
            "molecularProfile": {
                "id": 20201,
                "profileName": "PPM1D over exp"
            },
            "therapy": {
                "id": 3807,
                "therapyName": "CCT007093 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4977,
                    "pubMedId": 20576088,
                    "title": "RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576088"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8332,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT244747, Taxol (paclitaxel), and radiation triple therapy synergistically inhibited Chek1 activation, and resulted in growth inhibition of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27422809).",
            "molecularProfile": {
                "id": 26229,
                "profileName": "CHEK1 positive"
            },
            "therapy": {
                "id": 4674,
                "therapyName": "CCT244747 + Paclitaxel + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6591,
                    "pubMedId": 27422809,
                    "title": "CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422809"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11647,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the addition of Erbitux (cetuximab) to therapy with Taxol (paclitaxel), Platinol (cisplatin), and radiotherapy did not demonstrate increased clinical benefit over Taxol (paclitaxel) and Platinol (cisplatin) plus radiotherapy in esophageal cancer patients, with the experimental and control groups demonstrating similar median overall survival (19.7 mo vs. 19 mo, respectively (PMID: 28687830; NCT00566852).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6090,
                "therapyName": "Cetuximab + Cisplatin + Paclitaxel + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9684,
                    "pubMedId": 28687830,
                    "title": "Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28687830"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11626,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the addition of Afinitor (everolimus) to the combined treatment of Platinol (cisplatin) and Taxol (paclitaxel) in patients with triple-receptor negative breast cancer did not result in improved clinical response when compared to Platinol (cisplatin), Taxol (paclitaxel), and placebo, and resulted in greater adverse events (PMID: 28270498).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6083,
                "therapyName": "Cisplatin + Everolimus + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9672,
                    "pubMedId": 28270498,
                    "title": "A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270498"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1496,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Taxol (paclitaxel) and (Platinol) cisplatin decreased Id1 protein expression and cell viability in Id1-overexpressing human non-small cell lung cancer cell lines in culture and reduced tumor growth in xenograft models (PMID: 25344919).",
            "molecularProfile": {
                "id": 2610,
                "profileName": "ID1 over exp"
            },
            "therapy": {
                "id": 1812,
                "therapyName": "Cisplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1415,
                    "pubMedId": 25344919,
                    "title": "High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25344919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1495,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, non-small cell lung cancer patients with increased Id1 expression demonstrated increased survival following treatment with Taxol (paclitaxel) and Platinol (cisplatin) compared to patients with low Id1 expression (PMID: 25344919).",
            "molecularProfile": {
                "id": 2610,
                "profileName": "ID1 over exp"
            },
            "therapy": {
                "id": 1812,
                "therapyName": "Cisplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1415,
                    "pubMedId": 25344919,
                    "title": "High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25344919"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17054,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Platinol (cisplatin), Taxol (paclitaxel), and Keytruda (pembrolizumab) is in guidelines as first-line therapy for patients with lung squamous cell carcinoma with CD274 (PD-L1) expression of greater than or equal to 1% (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 6522,
                "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9957,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ACY-241 and Taxol (paclitaxel) resulted in increased efficacy in advanced solid tumor xenograft models, including pancreatic and ovarian (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4822).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5327,
                "therapyName": "Citarinostat + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7821,
                    "pubMedId": null,
                    "title": "Abstract 4822: Combination efficacy of the selective HDAC inhibitor ACY-241 and paclitaxel in solid tumor models",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4822.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1375,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aliqopa (copanlisib), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 1276,
                "therapyName": "Copanlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 245,
                    "pubMedId": 24170767,
                    "title": "BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24170767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4094,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3442,
                "therapyName": "Crizotinib + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13039,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Aromasin (exemestane), is indicated in guidelines for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6713,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12958,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6708,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13037,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6711,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12956,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Femara (letrozole) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6707,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13036,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6710,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13048,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6434,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12942,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Nolvadex (tamoxifen) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6704,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1503,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7152,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Demcizumab (OMP-21M18) and Taxol (paclitaxel) combination treatment inhibited tumor growth and suppressed cancer stem cells in patient-derived xenograft models of ovarian cancer (Cancer Res 2013;73(8 Suppl):Abstract nr 3725).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4385,
                "therapyName": "Demcizumab + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6109,
                    "pubMedId": null,
                    "title": "Anti-DLL4 (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/3725.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Dinaciclib (SCH 727965) and Taxol (paclitaxel) demonstrated enhanced growth inhibition in lung cancer cell lines in culture (PMID: 27550941).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4912,
                "therapyName": "Dinaciclib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6931,
                    "pubMedId": 27550941,
                    "title": "Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550941"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taxol (paclitaxel) efficacy was enhanced when combined with Disarib, resulting in greater cell death compared to either agent alone in B-cell acute lymphocytic leukemia cells in culture (PMID: 27693384).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6603,
                "therapyName": "Disarib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10633,
                    "pubMedId": 27693384,
                    "title": "A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27693384"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12074,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DKN-01 and Taxol (paclitaxel) combination treatment resulted in partial response in 18% (6/34) and stable disease in 32% (11/34) of advanced esophagogastric cancer patients, with a median progression-free survival of 13.7 weeks and an overall survival of 28.4 weeks (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 91P; NCT02013154).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6254,
                "therapyName": "DKN-01 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10009,
                    "pubMedId": null,
                    "title": "Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12075,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DKN-01 and Taxol (paclitaxel) combination treatment resulted in partial response in 18% (6/34) and stable disease in 32% (11/34) of advanced esophagogastric cancer patients, with a median progression-free survival of 13.7 weeks and an overall survival of 28.4 weeks (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #91P; NCT02013154).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6254,
                "therapyName": "DKN-01 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10009,
                    "pubMedId": null,
                    "title": "Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10456,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the combination of Afinitor (everolimus) and Taxol (paclitaxel) resulted in a partial response lasting over 13 months in a metastatic urothelial carcinoma patient harboring NF2 Y153fs*1, as well as ATM V2119fs*8, an ATR splice site mutation, and TP53 R280K, who had progressed on platinum-based chemotherapy and single agent Taxotere (docetaxel) therapy (PMID: 25630452).",
            "molecularProfile": {
                "id": 27471,
                "profileName": "ATM V2119fs ATR mutant NF2 Y153fs TP53 R280K"
            },
            "therapy": {
                "id": 5505,
                "therapyName": "Everolimus + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8466,
                    "pubMedId": 25630452,
                    "title": "Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25630452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5565,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 3896,
                "therapyName": "GSK2256098 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 363,
                "name": "uterine cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4669,
                    "pubMedId": 25833835,
                    "title": "PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25833835"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11170,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11169,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1398,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including patients with PIK3CA activating mutations (Annals of Oncology (2014) 25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331).",
            "molecularProfile": {
                "id": 743,
                "profileName": "PIK3CA act mut"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1146,
                    "pubMedId": null,
                    "title": "446PD - Phase Ib dose-escalation study of the Akt inhibitor ipatasertib (Ipat) with paclitaxel (P) in patients (pts) with advanced solid tumors",
                    "url": "http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Developmental-Therapeutics/Phase-Ib-dose-escalation-study-of-the-Akt-inhibitor-ipatasertib-Ipat-with-paclitaxel-P-in-patients-pts-with-advanced-"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11167,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients with low Pten expression (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",
            "molecularProfile": {
                "id": 13314,
                "profileName": "PTEN dec exp"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11168,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11166,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in patients with triple-receptor negative breast cancer (PMID: 28800861; NCT02162719).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                },
                {
                    "id": 9798,
                    "pubMedId": 28800861,
                    "title": "Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28800861"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JQ1 and Taxol (paclitaxel) resulted in a synergistic effect and inhibited the growth of triple-receptor negative breast cancer cells in culture (PMID: 27872098).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5415,
                "therapyName": "JQ1 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8148,
                    "pubMedId": 27872098,
                    "title": "Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872098"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5904,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-392 and Taxol (paclitaxel) worked synergistically to inhibit Src signaling and proliferation of triple-receptor negative breast cancer cell lines in culture, and induced tumor regression and suppressed metastasis in xenograft models (PMID: 22784709).",
            "molecularProfile": {
                "id": 1875,
                "profileName": "SRC positive"
            },
            "therapy": {
                "id": 3978,
                "therapyName": "KX2-391 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5190,
                    "pubMedId": 22784709,
                    "title": "Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22784709"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 939,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1410,
                "therapyName": "Lapatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 614,
                    "pubMedId": 24868024,
                    "title": "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24868024"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3359,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).",
            "molecularProfile": {
                "id": 430,
                "profileName": "PIK3CA wild-type"
            },
            "therapy": {
                "id": 3130,
                "therapyName": "Lapatinib + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3761,
                    "pubMedId": 26245675,
                    "title": "Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26245675"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4768,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LCL161 and Taxol (paclitaxel) inhibited proliferation of hepatocellular carcinoma cells in culture (PMID: 24976294).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3642,
                "therapyName": "LCL161 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4718,
                    "pubMedId": 24976294,
                    "title": "Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24976294"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5277,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2109761 and Taxol (paclitaxel) worked synergistically to inhibit the growth of triple-receptor negative breast cancer cell lines in culture (PMID: 20576088).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3809,
                "therapyName": "LY2109761 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4977,
                    "pubMedId": 20576088,
                    "title": "RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576088"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8861,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4841,
                "therapyName": "LY411575 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14485,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEDI3617 in combination with Taxol (paclitaxel) resulted in objective response in 15% (2/13) and stable disease in 31% (4/13) of patients with advanced solid tumors, with a median progression-free survival of 3.5 months (PMID: 29559563; NCT01248949).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7097,
                "therapyName": "MEDI3617 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11647,
                    "pubMedId": 29559563,
                    "title": "Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559563"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Taxol (paclitaxel) inhibited tumor growth and STAT signaling in non-small cell lung cancer cells harboring EGFR del E746-A750 and with intact autocrine IL6 signaling in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3482,
                "therapyName": "MEDI5117 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5553,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, the combination of MK2206 and Taxol (paclitaxel) was well tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors, with partial response in 24% (5/21) and stable disease in 43% (9/21) of patients (PMID: 25688104)",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3893,
                "therapyName": "MK2206 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5100,
                    "pubMedId": 25688104,
                    "title": "SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688104"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2925,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1892,
                "therapyName": "MM-111 + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3530,
                    "pubMedId": null,
                    "title": "Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer",
                    "url": "http://meetinglibrary.asco.org/content/106018-133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6713,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1892,
                "therapyName": "MM-111 + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5771,
                    "pubMedId": null,
                    "title": "Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166103.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 417,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III study, Motesanib plus Paraplatin (carboplatin) or Taxol (paclitaxel) improved overall survival, progression free survival and objective response rate for a subset of Asian patients with advanced nonsquamous non-small cell lung cancer (PMID:24419239; NCT00460317).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1695,
                "therapyName": "Motesanib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 97,
                    "pubMedId": 24419239,
                    "title": "Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24419239"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mps-BAY1, in combination with paclitaxel, had increased efficacy in inhibiting cell proliferation of colon carcinoma cell in culture (PMID: 23933817).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3453,
                "therapyName": "Mps-BAY1 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4417,
                    "pubMedId": 23933817,
                    "title": "Characterization of novel MPS1 inhibitors with preclinical anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23933817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4202,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mps-BAY2a, in combination with paclitaxel, had increased efficacy in inhibiting cell proliferation of colon carcinoma cell in culture (PMID: 23933817).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3454,
                "therapyName": "Mps-BAY2a + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4417,
                    "pubMedId": 23933817,
                    "title": "Characterization of novel MPS1 inhibitors with preclinical anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23933817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mps-BAY2b, in combination with paclitaxel, had increased efficacy in decreasing tumor volume of cervical carcinoma xenografts (PMID: 23933817).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3452,
                "therapyName": "Mps-BAY2b + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4417,
                    "pubMedId": 23933817,
                    "title": "Characterization of novel MPS1 inhibitors with preclinical anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23933817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mps-BAY2b, in combination with paclitaxel, had increased efficacy in inhibiting cell proliferation of colon carcinoma cell in culture (PMID: 23933817).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3452,
                "therapyName": "Mps-BAY2b + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4417,
                    "pubMedId": 23933817,
                    "title": "Characterization of novel MPS1 inhibitors with preclinical anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23933817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4319,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330).",
            "molecularProfile": {
                "id": 597,
                "profileName": "NOTCH1 wild-type"
            },
            "therapy": {
                "id": 3491,
                "therapyName": "MRK-003 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH2 rearrangement (PMID: 25104330).",
            "molecularProfile": {
                "id": 17811,
                "profileName": "NOTCH2 rearrange"
            },
            "therapy": {
                "id": 3491,
                "therapyName": "MRK-003 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4318,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330).",
            "molecularProfile": {
                "id": 17701,
                "profileName": "NOTCH1 rearrange"
            },
            "therapy": {
                "id": 3491,
                "therapyName": "MRK-003 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6814,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4263,
                "therapyName": "MYL-1401O + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5830,
                    "pubMedId": null,
                    "title": "Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.",
                    "url": "http://meetinglibrary.asco.org/content/162159-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8775,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II tiral, combination of BBI608 (Napabucasin) and Taxol (paclitaxel) demonstrated safety and clinical efficacy in patients with advanced gastric and gastroesophageal junction adenocarcinoma (J Clin Oncol 33, 2015 (suppl; abstr 4069)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2586,
                "therapyName": "Napabucasin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6739,
                    "pubMedId": null,
                    "title": "Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.",
                    "url": "http://meetinglibrary.asco.org/content/153561-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14180,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (BRIGHTER) trial, combination of Napabucasin (BBI608) and Taxol (paclitaxel) did not significantly improve overall survival (6.93 vs 7.36 months, HR=1.01, p=0.8596) or progression-free survival (3.55 vs 3.65 months, HR=1.00, p=0.9679) compared to placebo in patients with pretreated, advanced gastric and gastroesophageal junction adenocarcinoma (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4010-4010; NCT02178956).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2586,
                "therapyName": "Napabucasin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11490,
                    "pubMedId": null,
                    "title": "The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4010"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8774,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II tiral, combination of BBI608 (Napabucasin) and Taxol (paclitaxel) demonstrated safety and clinical efficacy in patients with advanced gastric and gastroesophageal junction adenocarcinoma (J Clin Oncol 33, 2015 (suppl; abstr 4069)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2586,
                "therapyName": "Napabucasin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6739,
                    "pubMedId": null,
                    "title": "Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.",
                    "url": "http://meetinglibrary.asco.org/content/153561-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14179,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (BRIGHTER) trial, combination of Napabucasin (BBI608) and Taxol (paclitaxel) did not significantly improve overall survival (6.93 vs 7.36 months, HR=1.01, p=0.8596) or progression-free survival (3.55 vs 3.65 months, HR=1.00, p=0.9679) compared to placebo in patients with pretreated, advanced gastric and gastroesophageal junction adenocarcinoma (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4010-4010; NCT02178956).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2586,
                "therapyName": "Napabucasin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11490,
                    "pubMedId": null,
                    "title": "The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4010"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and Taxol (paclitaxel) resulted in a synergistic effect and inhibited the growth of triple-receptor negative breast cancer cells in culture (PMID: 27872098).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5413,
                "therapyName": "Navitoclax + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8148,
                    "pubMedId": 27872098,
                    "title": "Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872098"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9585,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 5101,
                "therapyName": "Neratinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7298,
                    "pubMedId": 27078022,
                    "title": "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27078022"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Nutlin-3 and Taxol (paclitaxel) resulted in a synergistic effect and inhibited the growth of triple-receptor negative breast cancer cells in culture (PMID: 27872098).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5414,
                "therapyName": "Nutlin-3 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8148,
                    "pubMedId": 27872098,
                    "title": "Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872098"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5946,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627).",
            "molecularProfile": {
                "id": 21622,
                "profileName": "JAK2 over exp"
            },
            "therapy": {
                "id": 3991,
                "therapyName": "NVP-BSK805 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5204,
                    "pubMedId": 27075627,
                    "title": "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27075627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5947,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).",
            "molecularProfile": {
                "id": 22035,
                "profileName": "JAK2 amp"
            },
            "therapy": {
                "id": 3991,
                "therapyName": "NVP-BSK805 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5204,
                    "pubMedId": 27075627,
                    "title": "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27075627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12606,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).",
            "molecularProfile": {
                "id": 22423,
                "profileName": "ATM negative"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10476,
                    "pubMedId": 29103871,
                    "title": "Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29103871"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8766,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658; NCT01063517).",
            "molecularProfile": {
                "id": 1391,
                "profileName": "ATM dec exp"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6735,
                    "pubMedId": 26282658,
                    "title": "Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26282658"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8765,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (3.91 vs 3.55 months) compared to Taxol alone, but did significantly prolong overall survival (13.1 vs 8.3 months) in patients with metastatic gastric cancer (PMID: 26282658; NCT01063517).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6735,
                    "pubMedId": 26282658,
                    "title": "Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26282658"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12605,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (8.8 vs 6.9 months, HR=0.79, p=0.026) compared to Taxol (paclitaxel) alone in Asian patients with advanced gastric cancer (PMID: 29103871; NCT01924533).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10476,
                    "pubMedId": 29103871,
                    "title": "Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29103871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ONC201 and Taxol (paclitaxel) worked synergistically to inhibit viability of triple-negative breast cancer cell lines in culture (PMID: 28424227).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5978,
                "therapyName": "ONC201 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9294,
                    "pubMedId": 28424227,
                    "title": "ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16504,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xenical (orlistat) and Taxol (paclitaxel) synergistically inhibited growth and induced apoptosis in hepatocellular carcinoma cells in culture (PMID: 30667213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8072,
                "therapyName": "Orlistat + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13892,
                    "pubMedId": 30667213,
                    "title": "Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30667213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1487,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells that overexpressed HSBP1 demonstrated resistance to Abraxane (paclitaxel) in androgen-withdrawl cell culture conditions, and in castrated cell line xenograft models (PMID: 20101233)",
            "molecularProfile": {
                "id": 2601,
                "profileName": "HSBP1 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1385,
                    "pubMedId": 20101233,
                    "title": "Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20101233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, paclitaxel treatment of non-small cell lung carcinoma cells lines overexpressing Aurkb were sensitive to treatment, as demonstrated by a decrease in cell survival (PMID: 28095398).",
            "molecularProfile": {
                "id": 4417,
                "profileName": "AURKB over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14011,
                    "pubMedId": 28095398,
                    "title": "Aurora B expression modulates paclitaxel response in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28095398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13299,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, silencing of Atf1 expression enhanced the efficacy of paclitaxel in esophagus squamous cell carcinoma cells overexpressing Atf1, as demonstrated by inhibition of cell growth (PMID: 28912415).",
            "molecularProfile": {
                "id": 29070,
                "profileName": "ATF1 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11058,
                    "pubMedId": 28912415,
                    "title": "Targeting Overexpressed Activating Transcription Factor 1 (ATF1) Inhibits Proliferation and Migration and Enhances Sensitivity to Paclitaxel In Esophageal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28912415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5220,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Bcl2 expression through Bcl2-siRNA silencing potentiated the anti-tumor effect of Taxol (paclitaxel) in cell line xenograft models of glioblastoma (PMID: 19473291).",
            "molecularProfile": {
                "id": 20309,
                "profileName": "BCL2 dec exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4927,
                    "pubMedId": 19473291,
                    "title": "Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19473291"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5225,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCL2 over expression was associated with Taxol (paclitaxel) resistance in a panel of tumor cell lines through multiple factor analysis, and was predictive of Taxol (paclitaxel)-resistance in patient samples (PMID: 26372358).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4931,
                    "pubMedId": 26372358,
                    "title": "Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1427,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the siRNA knockdown of FOXA1 enhanced the efficacy of Taxol (paclitaxel) in ER-positive breast cancer cells, including Taxol (paclitaxel)-resistant cells in culture (PMID: 25422910).",
            "molecularProfile": {
                "id": 2518,
                "profileName": "FOXA1 dec exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1274,
                    "pubMedId": 25422910,
                    "title": "Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25422910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5229,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human lymphocytes over expressing Bcl2 demonstrated reduced sensitivity to Taxol (paclitaxel) induced apoptosis in culture (PMID: 10432288).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4932,
                    "pubMedId": 10432288,
                    "title": "Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10432288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16790,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, alternating sequential treatment with Ibrance (palbociclib) and Taxol (paclitaxel) resulted in a median progression-free survival (mPFS) of 209 days in patients with Rb1-positive breast cancer, with a mPFS of 802 days and a clinical benefit rate of 55.6% (5/9) at the recommended phase II dose (PMID: 30635336; NCT01320592).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 8198,
                "therapyName": "Paclitaxel + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14913,
                    "pubMedId": 30635336,
                    "title": "Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30635336"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2247,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Votrient (pazopanib) and Taxol (paclitaxel) demonstrated safety and resulted in partial response in 36% (10/28) and stable disease in 36% (10/28) of patients with advanced solid tumors (PMID: 25504632).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1143,
                "therapyName": "Paclitaxel + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2830,
                    "pubMedId": 25504632,
                    "title": "A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504632"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6414,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with urothelial carcinoma treated with the combination of Taxol (paclitaxel) and Votrient (pazopanib) demonstrated an overall response rate of 54% (15/28), in which 11% (3/28) experienced a complete response and 43% (12/28) experienced stable disease (PMID: 27068017).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1143,
                "therapyName": "Paclitaxel + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5569,
                    "pubMedId": 27068017,
                    "title": "Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27068017"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13050,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 1549,
                "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13051,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1549,
                "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5276,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mithracin (plicamycin) and Taxol (paclitaxel) worked synergistically to inhibit the growth of triple-receptor negative breast cancer cell lines in culture (PMID: 20576088).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3808,
                "therapyName": "Paclitaxel + Plicamycin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4977,
                    "pubMedId": 20576088,
                    "title": "RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576088"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 453,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) in combination with Taxol (paclitaxel) increased progression-free and overall survival and improved quality of life compared to treatment with Taxol (paclitaxel) alone in patients with advanced gastric cancer (PMID:24706672).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1721,
                "therapyName": "Paclitaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 200,
                    "pubMedId": 24706672,
                    "title": "Ramucirumab extends gastric cancer survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24706672"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2002,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) in combination with Taxol (paclitaxel) increased progression-free and overall survival and improved quality of life compared to treatment with Taxol (paclitaxel) alone in patients with gastroesophageal junction adenocarcinoma (PMID:24706672).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1721,
                "therapyName": "Paclitaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 200,
                    "pubMedId": 24706672,
                    "title": "Ramucirumab extends gastric cancer survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24706672"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12202,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Taxol (paclitaxel) and Reparixin in patients with metastatic ERBB2 (HER2)-receptor negative breast cancer resulted in a 30% (8/27) response rate and a durable response greater than 12 months in two patients (PMID: 28539464; NCT02001974).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6353,
                "therapyName": "Paclitaxel + Reparixin",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10154,
                    "pubMedId": 28539464,
                    "title": "Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539464"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2830,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Ridaforolimus (MK-8669), in combination with paclitaxel, produced stable disease greater than or equal to 4 months in 67% (2/3) of gastric cancer patients (PMID: 19901013).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3032,
                "therapyName": "Paclitaxel + Ridaforolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3494,
                    "pubMedId": 19901013,
                    "title": "Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19901013"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone  (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4840,
                "therapyName": "Paclitaxel + RO4929097",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 965,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",
            "molecularProfile": {
                "id": 23650,
                "profileName": "EGFR over exp ERBB2 dec exp"
            },
            "therapy": {
                "id": 1416,
                "therapyName": "Paclitaxel + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 625,
                    "pubMedId": 24886365,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24886365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15235,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SC13, in combination with Taxol (paclitaxel), enhanced sensitivity of cervical cancer cell lines and xenografts, overexpressing Fen1, as demonstrated by increased apoptosis and decreased tumor volume (PMID: 29358095).",
            "molecularProfile": {
                "id": 30880,
                "profileName": "FEN1 over exp"
            },
            "therapy": {
                "id": 7519,
                "therapyName": "Paclitaxel + SC13",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12954,
                    "pubMedId": 29358095,
                    "title": "Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29358095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6845,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a patient with CUL1-BRAF positive serous ovarian cancer experienced a sustained complete remission when treated with Selumetinib (AZD6244) and Taxol (paclitaxel), with remission lasting off therapy and for greater than 18 months of follow up (PMID: 26324360).",
            "molecularProfile": {
                "id": 23814,
                "profileName": "CUL1-BRAF"
            },
            "therapy": {
                "id": 4282,
                "therapyName": "Paclitaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5860,
                    "pubMedId": 26324360,
                    "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324360"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10749,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of sEphB4-HSA and Taxol (paclitaxel) resulted in complete remission in cell line xenograft models of Ephb4-positive non-small cell lung carcinoma (PMID: 23844053).",
            "molecularProfile": {
                "id": 27742,
                "profileName": "EPHB4 positive"
            },
            "therapy": {
                "id": 5605,
                "therapyName": "Paclitaxel + sEphB4-HSA",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4341,
                    "pubMedId": 23844053,
                    "title": "The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23844053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5315,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SPC3042 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in prostate cancer cell line xenograft models, with increased activity over either agent alone (PMID: 18790754).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3828,
                "therapyName": "Paclitaxel + SPC3042",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5012,
                    "pubMedId": 18790754,
                    "title": "SPC3042: a proapoptotic survivin inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18790754"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SRT1460 and Taxol (paclitaxel) inhibited growth of human pancreatic cancer cell lines in culture, with greater efficacy compared to SRT1460 alone (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4157,
                "therapyName": "Paclitaxel + SRT1460",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SRT1720 and Taxol (paclitaxel) inhibited growth of human pancreatic cancer cell lines in culture, with increased efficacy over SRT1720 alone (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4158,
                "therapyName": "Paclitaxel + SRT1720",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11119,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination of Taladegib and Taxol (paclitaxel) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 3 patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2594)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5867,
                "therapyName": "Paclitaxel + Taladegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9093,
                    "pubMedId": null,
                    "title": "A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183751.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1136,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS-119 demonstrated synergistic effects with Taxol (paclitaxel) or Taxotere (docetaxel) in multiple tumor cell lines by promoting apoptosis (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1668,
                "therapyName": "Paclitaxel + TAS-119",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 557,
                    "pubMedId": null,
                    "title": "TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A268"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6813,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TRX-E-002-1 given as a maintenance treatment after Taxol (paclitaxel) treatment resulted in less tumor recurrence compared to placebo in cell line xenograft models of ovarian cancer (PMID: 27196760).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4261,
                "therapyName": "Paclitaxel + TRX-E-002-1",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5826,
                    "pubMedId": 27196760,
                    "title": "TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196760"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8738,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combining intraperitoneal Taxol (paclitaxel) with TS-1 (tegafur-gimeracil-oteracil potassium) and Taxol did not show statistical improvement of overall survival, but did demonstrated clinical efficacy compared to TS-1 and cisplatin combination in gastric adenocarcinoma patients with peritoneal metastasis (J Clin Oncol 34, 2016 (suppl; abstr 4014)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4805,
                "therapyName": "Paclitaxel + TS-1",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6723,
                    "pubMedId": null,
                    "title": "Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.",
                    "url": "http://meetinglibrary.asco.org/content/166629-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6548,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 6% (3/47) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6556,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in 58-98% reduction of CA-125 level in 42% (5/12) of ovarian cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6549,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6555,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response and a 58% reduction in CA-125 level in a peritoneal carcinoma patient (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 1791,
                "name": "peritoneal carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6553,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 8% (1/12) and stable disease for more than 20 weeks in 25% (3/12) of breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5053,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in one patient with peritoneal serous carcinoma (2015 51 S724-S724 Eur J Cancer\r\n).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 4901,
                "name": "peritoneal serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4866,
                    "pubMedId": null,
                    "title": "Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination",
                    "url": "https://www.researchgate.net/publication/282785628_Evidence_of_activity_of_a_new_mechanism_of_action_MoA_A_first-in-human_study_of_the_first-in-class_fatty_acid_synthase_FASN_inhibitor_TVB-2640_as_mon"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7165,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vantictumab (OMP-18R5) worked synergistically with Taxol (paclitaxel) to inhibit tumor growth in patient-derived xenograft models of breast cancer (PMID: 22753465).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4398,
                "therapyName": "Paclitaxel + Vantictumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6127,
                    "pubMedId": 22753465,
                    "title": "Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22753465"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7167,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Vantictumab (OMP-18R5) and Taxol (paclitaxel) was well-tolerated and demonstrated preliminary efficacy in patients with metastatic HER2-negative breast cancer (J Clin Oncol 34, 2016 (suppl; abstr 2516)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4398,
                "therapyName": "Paclitaxel + Vantictumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6128,
                    "pubMedId": null,
                    "title": "Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with Paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).",
                    "url": "http://meetinglibrary.asco.org/content/166396-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17240,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, VB-111 in combination with Taxol (paclitaxel) resulted in increased tumor lymphocyte infiltration and tumor necrosis in biopsies obtained from 3 patients with ovarian cancer (AACR Annual Meeting 2019, Abstract 4979).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8431,
                "therapyName": "Paclitaxel + VB-111",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15256,
                    "pubMedId": null,
                    "title": "Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3761"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Vistusertib (AZD2014) and Taxol (paclitaxel) inhibited growth of ovarian cancer cells in culture (AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 931).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1973,
                "therapyName": "Paclitaxel + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1776,
                    "pubMedId": null,
                    "title": "Abstract 931: The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/72/8_Supplement/931.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14534,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of Taxol (paclitaxel) and Vistusertib (AZD2014) resulted in a RECIST response rate of 35% (8/23) and a median progression-free survival of 5.8 months in patients with squamous non-small cell lung carcinoma (PMID: 30016392; NCT02193633).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1973,
                "therapyName": "Paclitaxel + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11735,
                    "pubMedId": 30016392,
                    "title": "Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30016392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14533,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of Taxol (paclitaxel) and Vistusertib (AZD2014) resulted in a RECIST response rate of 64% (16/25), a CA125 response rate of 52% (13/25), and a median progression-free survival of 5.8 months in patients with high grade serous ovarian cancer (PMID: 30016392; NCT02193633).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1973,
                "therapyName": "Paclitaxel + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11735,
                    "pubMedId": 30016392,
                    "title": "Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30016392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6338,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 4115,
                "therapyName": "Paclitaxel + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "therapies": [
        {
            "id": 7578,
            "therapyName": "ABBV-181 + ABT-165 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7576,
            "therapyName": "ABT-165 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3800,
            "therapyName": "Adavosertib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1567,
            "therapyName": "Adavosertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5470,
            "therapyName": "Ado-trastuzumab emtansine + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2442,
            "therapyName": "Afatinib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2441,
            "therapyName": "Afatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8020,
            "therapyName": "Afuresertib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7136,
            "therapyName": "Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel",
            "synonyms": "NANT non-small cell lung cancer vaccine combination"
        },
        {
            "id": 1679,
            "therapyName": "Alisertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1379,
            "therapyName": "Alpelisib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7559,
            "therapyName": "ALRN-6924 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2165,
            "therapyName": "Amuvatinib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6712,
            "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6706,
            "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 7370,
            "therapyName": "Anlotinib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5797,
            "therapyName": "APX005M + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8311,
            "therapyName": "ARQ 751 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5455,
            "therapyName": "ARQ092 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8640,
            "therapyName": "Aspirin + Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen",
            "synonyms": null
        },
        {
            "id": 6019,
            "therapyName": "ASTX-660 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2370,
            "therapyName": "Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1203,
            "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6881,
            "therapyName": "Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7730,
            "therapyName": "Atezolizumab + Ipatasertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5606,
            "therapyName": "Atezolizumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5600,
            "therapyName": "Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 8608,
            "therapyName": "AVB-S6-500 + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8609,
            "therapyName": "AVB-S6-500 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7326,
            "therapyName": "Avelumab + Carboplatin + Paclitaxel + Talazoparib",
            "synonyms": null
        },
        {
            "id": 1972,
            "therapyName": "Axitinib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5565,
            "therapyName": "AZD6738 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7544,
            "therapyName": "AZD9150 + Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3448,
            "therapyName": "BAY1161909 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3447,
            "therapyName": "BAY1217389 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4930,
            "therapyName": "Bazedoxifene + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6984,
            "therapyName": "Belinostat + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4555,
            "therapyName": "Bevacizumab + Capecitabine + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6528,
            "therapyName": "Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7489,
            "therapyName": "Bevacizumab + Carboplatin + Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7435,
            "therapyName": "Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8253,
            "therapyName": "Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin",
            "synonyms": null
        },
        {
            "id": 1487,
            "therapyName": "Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7735,
            "therapyName": "Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1152,
            "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2104,
            "therapyName": "Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1451,
            "therapyName": "Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2512,
            "therapyName": "Bevacizumab + Cisplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7515,
            "therapyName": "Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1486,
            "therapyName": "Bevacizumab + Cyclophosphamide + Doxorubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4836,
            "therapyName": "Bevacizumab + Emactuzumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1196,
            "therapyName": "Bevacizumab + Lurbinectedin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7702,
            "therapyName": "Bevacizumab + Olaparib + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 2123,
            "therapyName": "Bevacizumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7704,
            "therapyName": "Bevacizumab + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 2513,
            "therapyName": "Bevacizumab + Paclitaxel + Topotecan",
            "synonyms": null
        },
        {
            "id": 6255,
            "therapyName": "Bevacizumab-awwb + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7591,
            "therapyName": "BGB-A317 + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2010,
            "therapyName": "Binimetinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8027,
            "therapyName": "BMS-906024 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1183,
            "therapyName": "Buparlisib + Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1545,
            "therapyName": "Buparlisib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7542,
            "therapyName": "Capivasertib + Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2192,
            "therapyName": "Capivasertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1664,
            "therapyName": "Carboplatin + Cediranib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5720,
            "therapyName": "Carboplatin + Cemiplimab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1921,
            "therapyName": "Carboplatin + Cetuximab + Erlotinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1924,
            "therapyName": "Carboplatin + Cetuximab + Everolimus + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1989,
            "therapyName": "Carboplatin + Cetuximab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7140,
            "therapyName": "Carboplatin + Cisplatin + Docetaxel + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5873,
            "therapyName": "Carboplatin + Cisplatin + Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6736,
            "therapyName": "Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed",
            "synonyms": null
        },
        {
            "id": 1375,
            "therapyName": "Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6740,
            "therapyName": "Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed",
            "synonyms": null
        },
        {
            "id": 6738,
            "therapyName": "Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed",
            "synonyms": null
        },
        {
            "id": 2477,
            "therapyName": "Carboplatin + Cisplatin + Lapatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8603,
            "therapyName": "Carboplatin + Cisplatin + Nivolumab + Paclitaxel + Pemetrexed",
            "synonyms": null
        },
        {
            "id": 6132,
            "therapyName": "Carboplatin + Cisplatin + Paclitaxel + Pemetrexed",
            "synonyms": null
        },
        {
            "id": 5729,
            "therapyName": "Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1819,
            "therapyName": "Carboplatin + Dasatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6535,
            "therapyName": "Carboplatin + Defactinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7411,
            "therapyName": "Carboplatin + Docetaxel + MLN4924 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1827,
            "therapyName": "Carboplatin + Docetaxel + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3997,
            "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8325,
            "therapyName": "Carboplatin + Durvalumab + Paclitaxel + Tremelimumab",
            "synonyms": null
        },
        {
            "id": 3681,
            "therapyName": "Carboplatin + Enzalutamide + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5485,
            "therapyName": "Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1371,
            "therapyName": "Carboplatin + Erlotinib + Onartuzumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4581,
            "therapyName": "Carboplatin + Erlotinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2071,
            "therapyName": "Carboplatin + Fluorouracil + Paclitaxel + Vandetanib",
            "synonyms": null
        },
        {
            "id": 6265,
            "therapyName": "Carboplatin + Galunisertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5103,
            "therapyName": "Carboplatin + Ganetespib + Paclitaxel + Radiotherapy",
            "synonyms": null
        },
        {
            "id": 4785,
            "therapyName": "Carboplatin + Gedatolisib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8341,
            "therapyName": "Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin",
            "synonyms": null
        },
        {
            "id": 1488,
            "therapyName": "Carboplatin + Hydroxychloroquine + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5833,
            "therapyName": "Carboplatin + Imatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8194,
            "therapyName": "Carboplatin + INCMGA00012 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4400,
            "therapyName": "Carboplatin + Ipafricept + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7964,
            "therapyName": "Carboplatin + Ipatasertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5304,
            "therapyName": "Carboplatin + Ipilimumab + Nivolumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7478,
            "therapyName": "Carboplatin + Ipilimumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2476,
            "therapyName": "Carboplatin + Lapatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1885,
            "therapyName": "Carboplatin + Lenvatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2310,
            "therapyName": "Carboplatin + Linifanib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7869,
            "therapyName": "Carboplatin + M7824 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7098,
            "therapyName": "Carboplatin + MEDI3617 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1381,
            "therapyName": "Carboplatin + Metformin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6501,
            "therapyName": "Carboplatin + MLN4924 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6453,
            "therapyName": "Carboplatin + Motesanib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7761,
            "therapyName": "Carboplatin + Neratinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3234,
            "therapyName": "Carboplatin + Nintedanib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5303,
            "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5053,
            "therapyName": "Carboplatin + Nivolumab + Paclitaxel + Pemetrexed + Veliparib",
            "synonyms": null
        },
        {
            "id": 7734,
            "therapyName": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1370,
            "therapyName": "Carboplatin + Onartuzumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1190,
            "therapyName": "Carboplatin + Oregovomab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1124,
            "therapyName": "Carboplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3386,
            "therapyName": "Carboplatin + Paclitaxel + Panitumumab",
            "synonyms": null
        },
        {
            "id": 3202,
            "therapyName": "Carboplatin + Paclitaxel + Panobinostat",
            "synonyms": null
        },
        {
            "id": 1714,
            "therapyName": "Carboplatin + Paclitaxel + Pazopanib",
            "synonyms": null
        },
        {
            "id": 2103,
            "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 5054,
            "therapyName": "Carboplatin + Paclitaxel + Pemetrexed + Veliparib",
            "synonyms": null
        },
        {
            "id": 4235,
            "therapyName": "Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6266,
            "therapyName": "Carboplatin + Paclitaxel + PTC596",
            "synonyms": null
        },
        {
            "id": 1726,
            "therapyName": "Carboplatin + Paclitaxel + Ramucirumab",
            "synonyms": null
        },
        {
            "id": 5333,
            "therapyName": "Carboplatin + Paclitaxel + Ribociclib",
            "synonyms": null
        },
        {
            "id": 6690,
            "therapyName": "Carboplatin + Paclitaxel + Sapanisertib",
            "synonyms": null
        },
        {
            "id": 2640,
            "therapyName": "Carboplatin + Paclitaxel + Selinexor",
            "synonyms": null
        },
        {
            "id": 3428,
            "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
            "synonyms": null
        },
        {
            "id": 6027,
            "therapyName": "Carboplatin + Paclitaxel + Spartalizumab",
            "synonyms": null
        },
        {
            "id": 7327,
            "therapyName": "Carboplatin + Paclitaxel + Talazoparib",
            "synonyms": null
        },
        {
            "id": 6333,
            "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
            "synonyms": null
        },
        {
            "id": 2196,
            "therapyName": "Carboplatin + Paclitaxel + Trametinib",
            "synonyms": null
        },
        {
            "id": 1887,
            "therapyName": "Carboplatin + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6322,
            "therapyName": "Carboplatin + Paclitaxel + TSR-042",
            "synonyms": null
        },
        {
            "id": 5274,
            "therapyName": "Carboplatin + Paclitaxel + Veliparib",
            "synonyms": null
        },
        {
            "id": 1209,
            "therapyName": "Carboplatin + Paclitaxel + Vemurafenib",
            "synonyms": null
        },
        {
            "id": 6983,
            "therapyName": "Carboplatin + Paclitaxel + Vorinostat",
            "synonyms": null
        },
        {
            "id": 3135,
            "therapyName": "Carboplatin + Paclitaxel + XL147",
            "synonyms": null
        },
        {
            "id": 1663,
            "therapyName": "Carboxyamidotriazole Orotate  + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8271,
            "therapyName": "CB-839 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3807,
            "therapyName": "CCT007093 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4674,
            "therapyName": "CCT244747 + Paclitaxel + Radiotherapy",
            "synonyms": null
        },
        {
            "id": 1790,
            "therapyName": "Cetuximab + Cisplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6090,
            "therapyName": "Cetuximab + Cisplatin + Paclitaxel + Radiotherapy",
            "synonyms": null
        },
        {
            "id": 1988,
            "therapyName": "Cetuximab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7713,
            "therapyName": "CFI-402257 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4313,
            "therapyName": "Cirmtuzumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6083,
            "therapyName": "Cisplatin + Everolimus + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8378,
            "therapyName": "Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1812,
            "therapyName": "Cisplatin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6522,
            "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 1534,
            "therapyName": "Cisplatin + Paclitaxel + Sorafenib",
            "synonyms": null
        },
        {
            "id": 5327,
            "therapyName": "Citarinostat + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2208,
            "therapyName": "Cobimetinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1276,
            "therapyName": "Copanlisib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5943,
            "therapyName": "Crenolanib + Paclitaxel + Ramucirumab",
            "synonyms": null
        },
        {
            "id": 3442,
            "therapyName": "Crizotinib + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6713,
            "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6708,
            "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6711,
            "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6707,
            "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6236,
            "therapyName": "Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1505,
            "therapyName": "Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1504,
            "therapyName": "Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1495,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7723,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 6710,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6434,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 4679,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib",
            "synonyms": null
        },
        {
            "id": 6704,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1503,
            "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 7764,
            "therapyName": "Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6882,
            "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7722,
            "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 7765,
            "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1980,
            "therapyName": "Cyclophosphamide + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1898,
            "therapyName": "Cyclophosphamide + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 4385,
            "therapyName": "Demcizumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5581,
            "therapyName": "Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4912,
            "therapyName": "Dinaciclib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6603,
            "therapyName": "Disarib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6254,
            "therapyName": "DKN-01 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2282,
            "therapyName": "Docetaxel + Irinotecan + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3045,
            "therapyName": "Docetaxel + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6435,
            "therapyName": "Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 6936,
            "therapyName": "Docetaxel + Paclitaxel + Vinflunine",
            "synonyms": null
        },
        {
            "id": 1904,
            "therapyName": "Doxorubicin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7545,
            "therapyName": "Durvalumab + Oleclumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7541,
            "therapyName": "Durvalumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7543,
            "therapyName": "Durvalumab + Paclitaxel + Selumetinib",
            "synonyms": null
        },
        {
            "id": 7763,
            "therapyName": "EG12014 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4249,
            "therapyName": "Emactuzumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3725,
            "therapyName": "Enzalutamide + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5505,
            "therapyName": "Everolimus + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6670,
            "therapyName": "Fostamatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3541,
            "therapyName": "Galunisertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1579,
            "therapyName": "Ganetespib + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 3259,
            "therapyName": "Gemcitabine + Ibrutinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3896,
            "therapyName": "GSK2256098 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8293,
            "therapyName": "Ibrutinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1125,
            "therapyName": "Ifosfamide + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 6344,
            "therapyName": "INCB001158 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1172,
            "therapyName": "Iniparib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5548,
            "therapyName": "interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1588,
            "therapyName": "Ipatasertib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7605,
            "therapyName": "Ipilimumab + Nivolumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8122,
            "therapyName": "IPN60090 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5415,
            "therapyName": "JQ1 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3978,
            "therapyName": "KX2-391 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1410,
            "therapyName": "Lapatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3130,
            "therapyName": "Lapatinib + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 3642,
            "therapyName": "LCL161 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4236,
            "therapyName": "Lenvatinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2173,
            "therapyName": "Letrozole + Paclitaxel + Pegylated liposomal-doxorubicin + Tamoxifen",
            "synonyms": null
        },
        {
            "id": 1197,
            "therapyName": "Lurbinectedin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3809,
            "therapyName": "LY2109761 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4841,
            "therapyName": "LY411575 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7097,
            "therapyName": "MEDI3617 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3482,
            "therapyName": "MEDI5117 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3893,
            "therapyName": "MK2206 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5731,
            "therapyName": "MLN1117 + Paclitaxel + Sapanisertib",
            "synonyms": null
        },
        {
            "id": 2177,
            "therapyName": "MLN2480 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1892,
            "therapyName": "MM-111 + Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1695,
            "therapyName": "Motesanib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3453,
            "therapyName": "Mps-BAY1 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3454,
            "therapyName": "Mps-BAY2a + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3452,
            "therapyName": "Mps-BAY2b + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3491,
            "therapyName": "MRK-003 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4263,
            "therapyName": "MYL-1401O + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 2586,
            "therapyName": "Napabucasin + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5413,
            "therapyName": "Navitoclax + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5101,
            "therapyName": "Neratinib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3187,
            "therapyName": "Neratinib + Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 7433,
            "therapyName": "Nivolumab + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7431,
            "therapyName": "Nivolumab + Paclitaxel + Relatlimab",
            "synonyms": null
        },
        {
            "id": 5414,
            "therapyName": "Nutlin-3 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 3991,
            "therapyName": "NVP-BSK805 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 4807,
            "therapyName": "Olaparib + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 7701,
            "therapyName": "Olaparib + Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 5264,
            "therapyName": "OMP-305B83 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 5978,
            "therapyName": "ONC201 + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8072,
            "therapyName": "Orlistat + Paclitaxel",
            "synonyms": null
        },
        {
            "id": 1103,
            "therapyName": "Paclitaxel",
            "synonyms": null
        },
        {
            "id": 8198,
            "therapyName": "Paclitaxel + Palbociclib",
            "synonyms": null
        },
        {
            "id": 1995,
            "therapyName": "Paclitaxel + Panitumumab",
            "synonyms": null
        },
        {
            "id": 1143,
            "therapyName": "Paclitaxel + Pazopanib",
            "synonyms": null
        },
        {
            "id": 3574,
            "therapyName": "Paclitaxel + Pegylated liposomal-doxorubicin",
            "synonyms": null
        },
        {
            "id": 4021,
            "therapyName": "Paclitaxel + Pembrolizumab",
            "synonyms": null
        },
        {
            "id": 5956,
            "therapyName": "Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 7583,
            "therapyName": "Paclitaxel + Pembrolizumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1549,
            "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 1395,
            "therapyName": "Paclitaxel + Pexidartinib",
            "synonyms": null
        },
        {
            "id": 8261,
            "therapyName": "Paclitaxel + PF-05280014",
            "synonyms": null
        },
        {
            "id": 3808,
            "therapyName": "Paclitaxel + Plicamycin",
            "synonyms": null
        },
        {
            "id": 1721,
            "therapyName": "Paclitaxel + Ramucirumab",
            "synonyms": null
        },
        {
            "id": 8079,
            "therapyName": "Paclitaxel + Ramucirumab + TRK-950",
            "synonyms": null
        },
        {
            "id": 8702,
            "therapyName": "Paclitaxel + Ramucirumab + XOMA 052",
            "synonyms": null
        },
        {
            "id": 4433,
            "therapyName": "Paclitaxel + Rebastinib",
            "synonyms": null
        },
        {
            "id": 6353,
            "therapyName": "Paclitaxel + Reparixin",
            "synonyms": null
        },
        {
            "id": 3206,
            "therapyName": "Paclitaxel + Ribociclib",
            "synonyms": null
        },
        {
            "id": 3469,
            "therapyName": "Paclitaxel + Ricolinostat",
            "synonyms": null
        },
        {
            "id": 3032,
            "therapyName": "Paclitaxel + Ridaforolimus",
            "synonyms": null
        },
        {
            "id": 4840,
            "therapyName": "Paclitaxel + RO4929097",
            "synonyms": null
        },
        {
            "id": 1369,
            "therapyName": "Paclitaxel + Ruxolitinib",
            "synonyms": null
        },
        {
            "id": 1416,
            "therapyName": "Paclitaxel + Sapitinib",
            "synonyms": null
        },
        {
            "id": 7519,
            "therapyName": "Paclitaxel + SC13",
            "synonyms": null
        },
        {
            "id": 4282,
            "therapyName": "Paclitaxel + Selumetinib",
            "synonyms": null
        },
        {
            "id": 5605,
            "therapyName": "Paclitaxel + sEphB4-HSA",
            "synonyms": null
        },
        {
            "id": 1620,
            "therapyName": "Paclitaxel + Sonidegib",
            "synonyms": null
        },
        {
            "id": 3828,
            "therapyName": "Paclitaxel + SPC3042",
            "synonyms": null
        },
        {
            "id": 4157,
            "therapyName": "Paclitaxel + SRT1460",
            "synonyms": null
        },
        {
            "id": 4158,
            "therapyName": "Paclitaxel + SRT1720",
            "synonyms": null
        },
        {
            "id": 7594,
            "therapyName": "Paclitaxel + TAK-659",
            "synonyms": null
        },
        {
            "id": 5867,
            "therapyName": "Paclitaxel + Taladegib",
            "synonyms": null
        },
        {
            "id": 7114,
            "therapyName": "Paclitaxel + Talimogene laherparepvec",
            "synonyms": null
        },
        {
            "id": 1668,
            "therapyName": "Paclitaxel + TAS-119",
            "synonyms": null
        },
        {
            "id": 2322,
            "therapyName": "Paclitaxel + Taselisib",
            "synonyms": null
        },
        {
            "id": 5493,
            "therapyName": "Paclitaxel + Trametinib",
            "synonyms": null
        },
        {
            "id": 1551,
            "therapyName": "Paclitaxel + Trastuzumab",
            "synonyms": null
        },
        {
            "id": 5874,
            "therapyName": "Paclitaxel + Trastuzumab + TVB-2640",
            "synonyms": null
        },
        {
            "id": 3054,
            "therapyName": "Paclitaxel + Triciribine",
            "synonyms": null
        },
        {
            "id": 4261,
            "therapyName": "Paclitaxel + TRX-E-002-1",
            "synonyms": null
        },
        {
            "id": 4805,
            "therapyName": "Paclitaxel + TS-1",
            "synonyms": null
        },
        {
            "id": 3743,
            "therapyName": "Paclitaxel + TVB-2640",
            "synonyms": null
        },
        {
            "id": 4398,
            "therapyName": "Paclitaxel + Vantictumab",
            "synonyms": null
        },
        {
            "id": 8431,
            "therapyName": "Paclitaxel + VB-111",
            "synonyms": null
        },
        {
            "id": 1973,
            "therapyName": "Paclitaxel + Vistusertib",
            "synonyms": null
        },
        {
            "id": 1983,
            "therapyName": "Paclitaxel + Vorinostat",
            "synonyms": null
        },
        {
            "id": 4115,
            "therapyName": "Paclitaxel + XL147",
            "synonyms": null
        },
        {
            "id": 8333,
            "therapyName": "Paclitaxel + ZW25",
            "synonyms": null
        }
    ],
    "globalApprovalStatus": [
        
    ]
}